[
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Lead Plaintiffs United Association National Pension Fund ('UANPF') and Saskatchewan Healthcare Employees’ Pension Plan ('SHEPP') bring this securities class action on behalf of all purchasers of Carvana Co. ('Carvana') Class A common stock during the Class Period of May 6, 2020, to November 3, 2022 (inclusive), and a subclass of purchasers in Carvana's April 2022 public offering ('2022 Public Offering'). Defendants include Carvana (a used car e-commerce platform), Ernest Garcia III (CEO and co-founder), Mark Jenkins (CFO), Ernest Garcia II (controlling shareholder and father of Garcia III), Ryan Keeton (Chief Brand Officer and co-founder), and Benjamin Huston (COO and co-founder) (collectively, 'Exchange Act Defendants'). For Securities Act claims, additional defendants are Director Defendants (Michael Maroone, Neha Parikh, Ira Platt, Greg Sullivan), Stephen Palmer (VP Accounting), and underwriters Citigroup Global Markets Inc. and J.P. Morgan Securities LLC ('Securities Act Defendants').\n\nThe complaint alleges a 'pump-and-dump' scheme where Defendants artificially inflated Carvana's stock price by touting unsustainable retail unit sales growth fueled by: (i) lowering vehicle purchase/verification standards to buy low-quality cars from customers (inducing trade-ins); (ii) rapid expansion into 169+ distant markets without adequate inspection/reconditioning centers ('IRCs') or logistics infrastructure (creating $750+ extra costs per unit over 200 miles from IRCs); (iii) systematic violations of state title/registration laws (selling cars without title, issuing illegal out-of-state temporary tags, leading to fines, suspensions, probes); and (iv) pass-through sales with Garcia-affiliated DriveTime boosting units without profit. Defendants concealed logistical nightmares (third-party reliance, parking constraints, excess wholesale volume), unprofitable sales (manipulated Total GPU excluding outbound logistics/title costs; CarMax includes them), and regulatory risks while assuring scalable, 'capital-light,' 'Amazon-like' model with economies of scale.\n\nKey facts: 11 confidential witnesses (CWs) detail poor vehicle quality, overpaying, title delays (e.g., CW-3: 100 calls/week post-scheme; CW-4: 'huge mess'), logistics chaos; Garcia II sold $3.6B shares (modified 10b5-1 plans); others sold $280M+; stock soared to $376 (Aug. 2021), crashed 97%+ to $7.39 by Nov. 2022 end. Partial disclosures (e.g., WSJ/Barron's exposés, state suspensions in NC/MI/IL/PA/FL/TX/MD/OH/AZ, Q1-Q3 2022 results, ADESA $4.4B buy) caused drops.\n\nClaims: Exchange Act - Count I (§10(b)/10b-5 scheme/misstatements), Count II (§20(a) control liability), Count III (§20(A) insider trading vs. Garcia II/Jenkins/Keeton/Huston). Securities Act (2022 Offering) - Count IV (§11), Count V (§12(a)(2)), Count VI (§15 control). Significant dates: Class start (Q1 2020 earnings touting growth); peak sales Aug. 2021; NC suspension Aug. 2021; WSJ Oct. 2021; Q1 2022 miss/ADESA; layoffs May 2022; Barron's Jun. 2022; MI suspension Oct. 2022; Q3 2022 sales decline Nov. 2022.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under PSLRA, complaint must plead: (1) material misrepresentation/omission; (2) scienter; (3) connection with purchase/sale; (4) reliance; (5) economic loss; (6) loss causation (Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005)). Here, complaint pleads specific misstatements/omissions re: unsustainable growth drivers (lowered standards, distant markets, title violations), concealed costs/logistics/title risks, manipulated GPU (excluding outbound logistics/title vs. CarMax), with particularity via ¶¶200-285 (e.g., Q1 2020 call touting units/logistics despite known issues). Materiality: Omissions hid scheme fueling 74%+ unit growth but causing 300% logistics spike, ADESA need, declines. Scienter: Strong inference via core ops inference (Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007)); massive insider sales ($3.87B, timed pre-disclosures, modified 10b5-1s); CWs attributing knowledge to Defendants (e.g., CW-11/Huston Zoom on growth-over-ops); SOX certs. Reliance/loss causation: Fraud-on-market (Basic Inc. v. Levinson, 485 U.S. 224 (1988)); partial disclosures (e.g., WSJ/Barron's, suspensions, Q3 decline) caused 97% drop tied to truth emerging. Pleads plausible §10(b) claim; motion denied."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "§20(a) requires primary §10(b) violation + culpable control (e.g., 'power to direct/manage' + 'culpable participation' or power+use). Primary claim sustained supra. Individual Defendants (officers/controlling shareholder) had power/authority over ops/disclosures (¶¶27-28); directed scheme (CWs link to Garcia III/Huston/Jenkins); signed false filings/SOX. Garcia II's 84% voting control, related-party deals confirm. Culpable participation via scheme orchestration/sales. Motion denied."
        },
        {
          "claim": "Section 20(A) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "§20(A) imposes liability on insiders trading on material nonpublic info ('contemporaneous' trader purchases). Garcia II/Jenkins/Keeton/Huston sold $3.87B+ shares (Appendix A) while possessing MNPI re: scheme (poor quality buys, logistics/title risks). Complaint charts contemporaneous trades w/Plaintiffs (e.g., Garcia II Oct. 30, 2020 sales @ $195+ vs. UANPF buys @ $207-$184). Scienter/motive via core knowledge/sales volume (206x Jenkins salary). Pleads plausible claim; survives."
        },
        {
          "claim": "Section 11 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "§11 strict liability for registration statement material misstatements/omissions (negligence; no scienter) (Ernst & Ernst v. Hochfelder, 425 U.S. 185 (1976)). Plaintiffs trace direct 2022 Offering buys to Citigroup @ $80/share. Offering Docs (incorporating 2021 10-K) falsely touted 'capital-light'/scalable model, efficient logistics/inventory, quality acquisitions vs. traditional dealers (¶¶427-435), omitting scheme-driven issues (distant markets/logistics costs, low-quality buys/wholesale losses, title violations). Material: Risks understated (e.g., regulatory warnings generic vs. actual probes/suspensions). Underwriters due diligence defense unavailable pre-answer (Fed. R. Civ. P. 8). Negative causation affirmative defense (no loss) unripe (post-Offering drops tied to truths). Motion denied."
        },
        {
          "claim": "Section 12(a)(2) of the Securities Act",
          "ruling": "sustained",
          "reasoning": "§12(a)(2) liability for prospectus material misstatements/omissions in public offerings (strict liability to direct/offeror purchasers; reasonable care defense). Plaintiffs direct Offering buyers from underwriters. Prospectus repeated 10-K misstatements re: model advantages/logistics/acquisitions (¶¶427-435), omitting known risks/costs/title issues. 'Passed title' via underwriting. Motion denied."
        },
        {
          "claim": "Section 15 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "§15 control liability follows §11/12(a)(2) primary violations (+ control: 'power to direct' + 'guilty participation'). Primaries sustained supra. Individual Securities Act Defendants (signers/directors/officers) controlled issuer via positions/filings. Motion denied."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 99419,
      "completion_tokens": 1861,
      "total_tokens": 102101
    },
    "case_id": "azd-2_22-cv-02126"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Lead Plaintiff Glen Littleton brings this consolidated class action on behalf of all individuals and entities who purchased or sold Tesla securities (common stock, options, and other securities) during the Class Period of August 7, 2018, to August 17, 2018, and were damaged thereby, excluding defendants and affiliates. Defendants are Tesla, Inc., Elon Musk (Tesla's CEO and co-founder), and Tesla's Board of Directors (Brad W. Buss, Robyn Denholm, Ira Ehrenpreis, Antonio Gracias, James Murdoch, Kimbal Musk, and Linda Johnson Rice). The complaint alleges that Musk engaged in fraudulent conduct by tweeting on August 7, 2018, 'Am considering taking Tesla private at $420. Funding secured,' followed by additional tweets, an employee email published on Tesla's blog, and later statements claiming 'investor support is confirmed' with the deal contingent only on a shareholder vote. These statements created the false impression that a going-private transaction at $420 per share was imminent and fully funded, when in reality: no funding was secured; no key terms (including price) were discussed with potential investors like Saudi Arabia's Public Investment Fund (PIF); discussions with PIF were preliminary and contingent on contingencies like building a Middle East factory (a 'non-starter' for the Board); no advisors were retained; no shareholder interest assessed; no structure finalized for retail/institutional investors to remain post-privatization; and Musk viewed success odds at only 50% with 'a lot of uncertainty.' Tesla published Musk's misleading blog posts and employee email, and investor relations confirmed 'funding secured.' The Board failed to correct these misstatements promptly despite designating Musk's Twitter as an official disclosure channel in 2013. Key facts include: Musk's animosity toward short sellers (20% short interest); prior threats and stock buys to squeeze shorts; SEC investigation, complaints, and settlements where Musk/Tesla paid $20M each, Musk stepped down as Chairman, and admitted (without denying) statements were false based on 'baseless assumptions contrary to facts [he] knew'; stock surged 11% on Aug 7 (to $379.59, $1.1B short losses), then declined ~9% on Aug 17 after NYT revealed truth (to $305.50, wiping $5B+ market cap); massive volume/volatility damaged buyers at inflated prices, shorts forced to cover, and options traders. Legal claims: Count I - Section 10(b)/Rule 10b-5 against Tesla and Musk for material misrepresentations/omissions via scheme to defraud, artificially inflating/deflating prices, harming traders; Count II - Section 20(a) control person liability against Board for Tesla's primary violations. Significant dates: Aug 2 Musk emails Board tentative proposal; Aug 7 tweets/email/blog; Aug 13 blog; Aug 17 NYT corrective disclosure; Aug 24 abandonment announcement; Sept/Oct 2018 SEC settlements.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 against Tesla and Musk",
          "ruling": "sustained",
          "reasoning": "To survive a motion to dismiss a Section 10(b)/Rule 10b-5 claim, the complaint must plead: (1) a material misrepresentation or omission, (2) scienter, (3) connection to purchase/sale of security, (4) reliance, (5) economic loss, and (6) loss causation (Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005)); with PSLRA heightened particularity for falsity (supported by facts on which belief based) and scienter (strong inference of intent/recklessness). Here, falsity is plausibly pled with specificity: Musk's Aug 7 tweets ('Funding secured,' 'Investor support confirmed; only shareholder vote remains') and blog/email omitted material facts (no funding commitment, no $420 price discussion, PIF contingencies, 50% odds, no advisors/structure) and affirmatively misled on deal imminence, as detailed in ¶¶120-139, corroborated by SEC complaint (which Musk did not deny per 17 C.F.R. §202.5(e)), Musk's admissions (baseless assumptions contrary to known facts), and timeline (e.g., no post-July 31 PIF talks until Aug 10). Materiality obvious: stock jumped 11% ($36/share), 2x volume, analyst reports treated as substantive (RBC, Morningstar validating), volatility spiked. Scienter strongly inferred: Musk's knowledge from PIF meeting/Board talks/email (¶¶50-60); recklessness in tweeting without review despite warnings (reporter email); motive (anti-short crusade, convertible bond incentives); core operations inference; SEC settlement admissions. Reliance via fraud-on-the-market (Basic Inc. v. Levinson, 485 U.S. 224 (1988)) in efficient market (NASDAQ-listed, analyst coverage, high volume). Economic loss and loss causation: plausible for buyers (purchased inflated post-tweet, declined on revelations: Aug 8-17 drops totaling ~20%, tied to WSJ/SEC/NYT disclosures revealing falsity per Dura/Minerals Techs.); shorts/options via artificial inflation/volatility (mark-to-market/cover losses, implied vol surge). Connection satisfied as scheme disrupted trading. No PSLRA safe harbor (not forward-looking with meaningful cautionary language). Claims against both defendants: Musk direct; Tesla via ratification (IR confirmations), respondeat superior, senior authority."
        },
        {
          "claim": "Section 20(a) of the Securities Exchange Act of 1934 against the Board of Directors",
          "ruling": "dismissed",
          "reasoning": "Section 20(a) imposes control person liability on any person who 'controls' a primary violator of Section 10(b) with 'culpable participation' (28 U.S.C. §78t(a)); requires primary violation (assumed arguendo), plus: (1) power/control over primary violator's management/decisions, and (2) direct/indirect culpable involvement (Parmalat Capital Fin. Ltd. v. City of Madison, 671 F.3d 261 (2d Cir. 2012)). PSLRA rejects group pleading; individualized allegations needed. Complaint fails both elements. Control: Mere director status insufficient post-Twombly; no facts Board controlled Musk's impulsive Aug 7 tweet (posted en route to airport, no pre-approval despite Twitter designation; IR reacted post-facto). Board's post-tweet actions (Aug 8 press release vague, Aug 14 special committee) show reaction, not prior control over statements (Gracias post-tweet tweet restraint directive). Culpability: No allegations Board knew falsity pre-tweet (Musk emailed tentative Aug 2 proposal privately; Aug 3 call disclosed preliminary PIF interest); no participation in misstatements (vague Aug 8 statement neither affirmed/denied 'secured'); failed oversight generalized, not deliberate recklessness (e.g., no specific inaction despite red flags). SEC settlement targeted Musk/Tesla controls, not Board culpability. Dismissal without prejudice to replead."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 27527,
      "completion_tokens": 1512,
      "total_tokens": 30268
    },
    "case_id": "cand-3_18-cv-04865"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiff Fiyyaz Pirani, Trustee of Imperium Irrevocable Trust, brings this securities class action individually and on behalf of all persons and entities that purchased or acquired Netflix, Inc. common stock or call options, or sold put options, between January 19, 2021, and April 19, 2022 (the 'Class Period'). Defendants are Netflix, Inc. and its executives: Reed Hastings (Co-CEO), Ted Sarandos (Co-CEO), Spencer Neumann (CFO), and Gregory Peters (COO) (collectively, 'Individual Defendants'). Netflix operates a streaming platform reliant on paid memberships for revenue, with 'paid net adds' as a key investor metric. The complaint alleges Defendants engaged in fraudulent conduct by making material misrepresentations and omissions regarding the extent of 'account sharing' (password sharing outside households), which substantially inflated reported market penetration rates and hindered subscriber growth. Key factual allegations include: (1) Defendants repeatedly stated UCAN penetration was ~60% and global ~24-25%, assuring 'ample runway' and 'headroom' for growth, while omitting that ~30 million additional UCAN households and ~100 million globally were sharing accounts, yielding effective penetration of ~83-84% in UCAN and ~35-36% globally; (2) Defendants attributed subscriber growth slowdowns to 'COVID pull-forward' and 'choppiness,' claiming healthy underlying metrics (engagement, retention), despite knowing from internal monitoring (e.g., Synamedia software trial since 2019, IP tracking, memos, FE1/FE2 accounts of discussions as 'lost revenue' limiting goals), strategy sessions, and tests that sharing caused saturation; (3) historical permissive stance shifted post-COVID, with tests starting ~2021, but downplayed as routine; (4) partial truth emerged January 20, 2022 (Q4'21 miss, weak Q1'22 guidance blamed on COVID/macro, stock fell 21.7% to $397.50); full disclosure April 19, 2022 (admitted 100M+ sharers, high penetration headwinds with COVID obscuring issue, Q1'22 loss, stock fell 35% to $226.19). Claims asserted: (1) §10(b)/Rule 10b-5 violation against all Defendants for material misstatements/omissions in earnings calls, shareholder letters, 10-K/Qs; (2) §20(a) control person liability against Individual Defendants. Significant dates: Class Period start January 19, 2021 (Q4'20 results, 60% UCAN claim); end April 19, 2022 (admissions); drops January 21/April 20, 2022.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under the PSLRA, the complaint must plead with particularity: (1) a material misrepresentation or omission, (2) scienter, (3) connection with the purchase or sale of a security, (4) reliance upon the misrepresentation or omission, (5) economic loss, and (6) loss causation (Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005); Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007)). Fraud-on-the-market presumption applies given NFLX's efficient market trading on NASDAQ (Basic Inc. v. Levinson, 485 U.S. 224 (1988); Amgen Inc. v. Conn. Ret. Plans & Trust Funds, 568 U.S. 455 (2013)).\n\nMaterial Misrepresentation/Omission: Complaint pleads specific statements (e.g., ¶131 Neumann's '60% penetrated' UCAN/'lot of headroom'; ¶133 'long-term growth trajectory as strong as ever'; ¶172 repeated 60%) and omissions (extent of sharing: ~30M UCAN/~100M global households, stable % 'over years' per ¶192), rendering metrics (penetration, net adds, engagement/churn) misleading. Later admissions (April 19, 2022 Letter: 'over 100m additional households' causing 'high household penetration...revenue growth headwinds,' obscured by COVID) and analyst reactions (¶125: 'sea change,' saturation conceded) establish falsity/materiality—reasonable investor would view ~25-point penetration understatement as altering total mix (Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011)). Risk disclosures (10-Ks ¶135,170) hypothetical ('if abused/efforts ineffective') when abuse known/materialized. Not mere puffery (growth 'healthy,' 'runway') as tied to quantifiable metrics contradicted by specifics.\n\nScienter: Strong inference of intent/recklessness via: (1) core business—subscriber growth central (¶180, 10-K); (2) access/control (high-level positions, signed filings, earnings prep); (3) specific knowledge allegations (FE1: Q2'20 memo halting crackdown; FE2: quarterly reviews quantifying sharing as 'lost revenue'/IP data; ¶189-191); (4) evasive responses to probes (¶187-188); (5) testing/memos since 2019 (¶186); (6) SARs unnecessary as core ops + temporal proximity to admissions/disclosures (Tellabs 'holistic' view). Motive (sustain growth narrative amid comp) + GAAP compliance not rebut. Inference at least as compelling as nonfraud.\n\nReliance/Loss/Economic Loss/Loss Causation: Fraud-on-market; post-Class drops on partial (Jan. 20/21: 21.7% on growth miss) and full (Apr. 19/20: 35% on sharing/penetration reveal) disclosures tether losses to truth emergence (¶176-177; Miner v. Clinton Chevrolet, 543 F.3d 903 (9th Cir. 2008)—N.D. Cal. venue).\n\nPSLRA particularity satisfied; plausible §10(b) claim. Motion denied."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "§20(a) requires: (1) primary §10(b) violation by controlled entity/person; (2) culpable control (power to influence/direct + use thereof) (28 U.S.C. §78t(a); Paracor Fin., Inc. v. Gen. Elec. Co., 96 F.3d 1151 (9th Cir. 1996)). Primary survives (supra), shifting burden.\n\nIndividual Defendants culpable controllers: Senior execs (Co-CEOs, CFO, COO) with 'power/authority to control contents' of reports/press (¶31); signed misleading 10-K/Qs/8-Ks (¶135,146,154,170); prepared/disseminated statements (earnings calls, letters); privy to internal data (FE reports to Hastings/Peters chain ¶32-34); directed testing/strategy. 'Direct/supervisory involvement' + influence over ops/decisions pleads control exercised re: omissions (Howard v. Everex Sys., Inc., 228 F.3d 1057 (9th Cir. 2000)). No heightened culpability at pleading stage (Larkin v. GlaxoSmithKline, 2013 WL 5863015 (N.D. Cal. 2013)). Motion denied."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 44188,
      "completion_tokens": 1619,
      "total_tokens": 46961
    },
    "case_id": "cand-4_22-cv-02672"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "The Consolidated Class Action Complaint alleges violations of federal securities laws arising from Defendants' materially false and misleading statements and omissions regarding the development, testing, regulatory approval, manufacturing capabilities, and commercialization prospects of Talis Biomedical Corporation's ('Talis') Talis One point-of-care molecular diagnostic device for COVID-19 testing. Plaintiffs are Lead Plaintiffs Martin Dugan, Leon Yu, and Max Wisdom Technology Limited, bringing claims on behalf of two classes: (1) for Securities Act claims, all persons who purchased Talis common stock pursuant or traceable to the February 11, 2021 IPO Registration Statement and were damaged; (2) for Exchange Act claims, all persons who purchased Talis stock from March 30, 2021 (2020 10-K filing) to March 15, 2022 (end of class period, 2021 10-K and earnings call) and were damaged. Defendants include Talis; Securities Act Individual Defendants (former CEO Brian Coe, CFO J. Roger Moody, Jr., and directors Felix Baker, Raymond Cheong, Melissa Gilliam, Rustem F. Ismagilov, Kimberly J. Popovits, Matthew L. Posard, Randal Scott); Exchange Act Officer Defendants (Coe, Moody, Robert J. Kelley (current CEO)). Key allegations: At IPO, Talis concealed that its FDA EUA submission used an insufficiently sensitive comparator assay (contrary to FDA guidance), leading to swift FDA rejection days after IPO (disclosed March 8, 2021); Talis One had known design flaws, high invalid rates (>10%), leaking cartridges, and no realistic path to scale manufacturing 1 million cartridges/month or deliver 5,000 instruments (actually only ordered components); post-IPO statements in 10-K/10-Q filings and earnings calls (e.g., May 11, August 10, November 15, 2021) falsely claimed manufacturing 'on track,' 'ready to go,' 'final stages of validation,' and 'terrific results,' omitting known delays and issues. Supported by detailed accounts from five former employees (FEs: senior engineers, scientists, sales), internal schedules missed, RADx/NIH contract reporting, executive departures (Coe Aug. 2021, Blaser after 1 week Dec. 2021, COO Liu March 2022), and later admissions (March/May 2022: no launch timeline, high invalid rates, only components ordered). Stock traded from IPO $16/share (popped to $27.80), declined sharply post-disclosures (e.g., -12% March 8, -23% March 16, 2022), to $0.81 by June 2022. Claims: §§11/15 Securities Act (IPO Registration Statement misstatements/omissions re: EUA testing, manufacturing, product reliability; Item 303/105 violations); §§10(b)/20(a) Exchange Act (post-IPO statements). No fraud pled for Securities Act claims.",
      "claim_rulings": [
        {
          "claim": "Section 11 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Under Section 11, plaintiffs need only allege material misstatements or omissions in the Registration Statement with traceable purchases and damages; no scienter, reliance, or loss causation required at pleading stage (strict liability for issuer; due diligence defense affirmative). Complaint plausibly alleges specific actionable statements/omissions: (1) touting 'high PPA/NPA' and '100% agreement' with 'FDA-authorized' comparators while omitting use of insufficiently sensitive comparator assay (per FE-2, FDA guidance), rendering claims misleading and dooming EUA (material as EUA critical for commercialization/revenue); (2) false claim 'ordered 5,000 instruments' for Q1 2021 delivery (later admitted 'components for up to 5,000' through Q3 2021); (3) manufacturing claims of lines to 'scale to full capacity' 1M cartridges/month in 2021 despite known delays/missed internals (FEs 1-3), design issues; (4) 'highly accurate' product despite known high invalid rates/design flaws (FEs 2,4,5); (5) Item 303 omissions of known trends/uncertainties (flawed EUA, invalid rates, delays) reasonably likely to materially impact revenues; Item 105 failure to disclose specific risks beyond boilerplate. Statements not mere puffery; half-truths requiring context. No negative causation pled against; survives Iqbal/Twombly as plausible. Motion denied."
        },
        {
          "claim": "Section 15 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Section 15 imposes control person liability derivative of primary Section 11 violation, requiring plausible control (power to direct/influence) and culpable participation (negligent failure of reasonable investigation). Primary claim sustained; Individual Defendants (signers: Coe, Moody, directors) plausibly controlled as officers/directors approving content. Complaint alleges they negligently failed due diligence: ignored FDA 'additional info' request signaling comparator issues; overlooked internal testing/FEs on invalid rates/delays; no review of contracts/NIH reports despite core product/IPO timing. Experienced in biotech/diagnostics (e.g., Baker PhD, Popovits ex-CEO); facts discoverable via reasonable inquiry. No due diligence defense established at pleading. Survives as derivative."
        },
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal, complaint must plead: (1) material misrepresentation/omission; (2) scienter; (3) reliance (FOTM); (4) economic loss; (5) loss causation (materialization of risk). Efficient market pled. Materiality: Post-IPO statements in 10-K/Qs/earnings calls (e.g., 2020 10-K/1Q/2Q/3Q 10-Qs repeating 'ordered 5,000 instruments'/'scale to 1M cartridges 2021'; May 11: Moody 'on track,' Coe 'ready to go'; Aug 10: 'final stages validation'/'terrific results'; Nov: 'ramp up by end 2021') false/misleading per later admissions (components only; no validation till Nov 2021; high invalids), omitting known issues (FEs, contracts). Not protected PSLRA safe harbor (mixed present/historical facts; IPO carve-out inapplicable; inadequate cautions). Scienter: Strong inference via core operations (sole product, cash burn); FEs (detailed roles/tenures/personal knowledge: FE-1 to Moody subordinate; FE-3 briefed Coe; high invalids pre-EUA); access (RADx/thinXXS reporting; FDA invalid tracking); repeated specific statements; departures (Coe/Liu timed to admissions, Blaser 'fraud'). Holistic: motive (preserve facade post-IPO failure); GAAP-like Item 303. Loss causation: Partial corrections (March 8 EUA withdraw -12%; Aug 10 delays -6%; Aug 30 Coe exit -11%; Nov 15 phased -18%; March 15 no launch/invalids/layoffs -23%) with analyst reactions. Plausibly pleads all elements; motion denied."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "Control person liability derivative of primary §10(b) violation, requiring (1) primary violation; (2) control (power to direct + culpable participation). Primary sustained. Officer Defendants (Coe CEO, Moody CFO, Kelley CCO/CEO) plausibly controlling: signed/certified filings; made calls statements; directed operations. Culpable: same scienter facts (access/FE briefs/core ops). Survives as derivative."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 39322,
      "completion_tokens": 1665,
      "total_tokens": 41904
    },
    "case_id": "cand_22_cv_00105"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Lead Plaintiff Sjunde AP-Fonden ('AP7') brings this securities class action on behalf of all persons and entities who purchased or acquired Lucid Group, Inc. ('Lucid' or 'Company') common stock from November 15, 2021, to August 3, 2022 (Class Period), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Defendants are Lucid (Delaware corporation designing luxury EVs, trading as 'LCID'), Peter Rawlinson (CEO/CTO), and Sherry House (CFO) (collectively 'Individual Defendants'). The complaint alleges Defendants concealed severe internal, Company-specific production problems at Lucid's sole Arizona manufacturing plant (AMP-1) and Tempe warehouse, including dysfunctional inventory systems (e.g., failed SAP implementations, manual Excel tracking), warehouse overcapacity leading to crushed/destroyed parts ($20-30M/month scrapped), inability to locate/ship parts timely (causing frequent line shutdowns/hot calls), design flaws requiring post-production changes/out-of-spec parts, and refusal to conduct full physical inventories to avoid 'impacting books.' Instead, Defendants blamed transient external 'industry-wide supply chain/logistics challenges' they claimed to be 'mitigating,' while repeatedly affirming unrealistic 2022 production guidance for Lucid Air (sole revenue source): 20,000 vehicles (Nov 2021-Feb 2022), then 12,000-14,000 (Feb-May 2022), knowing internally (per FE-2) Lucid would produce <10,000 due to these issues. Rawlinson personally visited sites, received reports, and heard admissions (e.g., FE-1 warnings). Motive: Rawlinson vested ~$263M in performance RSUs via inflated market cap; Lucid raised $2B convertible notes at peak. Partial truths emerged: Feb 28, 2022 (slash to 12-14k, stock -13%); Aug 3, 2022 (slash to 6-7k, admitting 'immature logistics processes' as 'primary bottlenecks,' stock -9.7%). Key dates: Production start Sep 2021; 1st deliveries Oct 2021; Class Period start Nov 15, 2021 (3Q21 results reaffirming 20k); end Aug 3, 2022 (2Q22 results). Claims: Count I (§10b/Rule 10b-5 vs. all); Count II (§20(a) vs. Individuals).",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and SEC Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under PSLRA, complaint must plead: (1) material misrepresentation/omission; (2) scienter; (3) connection with purchase/sale of security; (4) reliance; (5) economic loss; (6) loss causation (Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005)). Here, all elements plausibly alleged. Falsity: Specific statements (e.g., Nov 15, 2021 earnings: 'confident in 20,000 units,' blaming 'industry-wide' supply chains while claiming mitigation; repeated through May 2022) materially misleading as half-truths omitting known internal facts making them false (Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011)). CW allegations (10 FEs in logistics/manufacturing) detail core problems from summer 2021 (e.g., FE-1/FE-2/FE-4/FE-8: warehouse 'chaos'/overcapacity, SAP failures, 90% stoppages logistics-driven, <10k known Oct/Nov 2021), corroborated by Defendants' Aug 2022 admission ('immature logistics' as 'primary bottlenecks'). No bespeaks caution/PSLRA safe harbor: statements not purely forward-looking/mixing historical facts, meaningless warnings (e.g., generic supply chain risks ignore internal issues), known falsity (Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (2015)). Scienter: Strong inference via core operations (production Lucid's 'laser focus'/sole revenue, Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007)); Rawlinson's visits/reports (FE-1 direct warnings, daily PM/AM reports, CTO meetings); internal admissions (FE-2: Rawlinson said <10k confidentially); motive (Rawlinson $263M RSUs vested on inflated cap, Lucid $2B notes); refusal physical inventory/failed fixes (e.g., Warehouse on Wheels); temporal proximity (20k to 12-14k in 2 weeks, then halved). Reliance/loss causation: Efficient market, corrective disclosures (Feb/Aug 2022) caused -13%/-9.7% drops tied to truth emergence (stock surges post-false affirmations). Pleadings exceed Iqbal/Twombly; discovery warranted."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "Section 20(a) requires primary violation (§10b/10b-5) and 'control person' status (culpable participation not required pre-Janus (Parmalat Capital Fin. Ltd. v. City of Madison Pension Trust, 671 F.3d 261 (2d Cir. 2012)), but allegations suffice). Primary violation pled (above). Control: Rawlinson/House as CEO/CFO had 'power to direct/direct influence' (17 C.F.R. §240.12b-2 'control'); signed filings/earnings scripts, controlled disclosures on core production ops. Culpability: Same scienter facts (visits, reports, motives). Motion denied."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 75137,
      "completion_tokens": 1275,
      "total_tokens": 76992
    },
    "case_id": "cand_22_cv_02094"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "The Amended Class Action Complaint is brought by Lead Plaintiff New England Teamsters Pension Fund, on behalf of a class of purchasers of Cutera, Inc. (CUTR) common stock during the Class Period from March 1, 2022, through March 21, 2024, who were damaged thereby. Defendants include Cutera, a Delaware corporation providing laser-based aesthetic and dermatological solutions, and Individual Defendants: David Mowry (former CEO), Rohan Seth (former CFO), J. Daniel Plants (former Chairman and Executive Chairman), Sheila Hopkins (former Interim CEO and Board member), Taylor Harris (current CEO and Board member), Stuart Drummond (current CFO), and Vikram Varma (former SVP and General Counsel). The alleged misconduct centers on Defendants' failure to maintain adequate internal controls over inventory and financial reporting, exacerbated by a rushed rollout of Cutera's new acne laser device, AviClear, motivated by executive compensation incentives (AviClear Incentive Plan or 'Acne Equity Grant') tied to device placements rather than utilization or revenue. Key factual allegations include: obsolete and botched implementation of ERP/SAP and Salesforce systems without proper training or oversight, leading to inventory mismatches, double-counting of returns (especially AviClear), a four-week plant shutdown for inventory audit, supply chain failures, quality/reliability issues causing device breakdowns and customer dissatisfaction/returns, and diversion of sales/manufacturing resources from core capital equipment and consumables business (which comprised ~91-98% of revenue) to AviClear, harming overall performance. Supported by 8 confidential witnesses (former employees detailing direct knowledge to executives like Mowry), public admissions (e.g., material weaknesses in ITGC, inventory controls, stock-based comp; restatements for Q1/Q2 2023 overstating inventory/understating costs/gross margins/operating losses), and a series of partial corrective disclosures from January 9, 2023 (revenue miss tied to AviClear focus), through March 21, 2024 (excess AviClear inventory, $8M reserves, 300/1200 device returns), causing cumulative stock drops exceeding 90% from Class Period highs. Despite SOX certifications and statements touting AviClear success, core strength, and effective controls, Defendants concealed these issues. Claims: (1) §10(b)/Rule 10b-5(b) against all Defendants for material misstatements/omissions; (2) §20(a) control person liability against Individual Defendants. Fraud-on-the-market reliance presumed given efficient Nasdaq market.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5(b)",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under Fed. R. Civ. P. 12(b)(6), the complaint must plead a plausible §10(b) claim under Iqbal/Twombly, requiring: (1) material misrepresentation or omission; (2) scienter; (3) connection with purchase/sale of security; (4) reliance; (5) economic loss; and (6) loss causation (Dura Pharms.). Here, all elements are plausibly pled. Material misrepresentations/omissions: Complaint details specific false statements in earnings calls, press releases, and SEC filings (e.g., touting AviClear 'success,' core business 'momentum,' effective internal controls/SOX certifications) contradicted by contemporaneous facts (CW reports of customer returns/dissatisfaction, inventory chaos, resource diversion), later admissions (material weaknesses in ITGC/inventory, restatements adjusting gross margins down 12%/8%, inventory overstated $1.2M/$3.6M), and operational harms (plant shutdown, double-counted returns). Statements like 'successful launch' and 'strong core' were core operational representations, not puffery, as they induced analyst optimism. Scienter: Strong inference under Tellabs via motive (Individual Defendants' bonuses tied to AviClear placements, achieved before truth emerged), core operations inference (AviClear/internal controls central to business), and red flags (CW direct reports to Mowry et al., SOX certs despite known issues, suspicious terminations 'with cause' tied to AviClear failures). Holistic view favors scienter over nonculpable explanations. Reliance: Fraud-on-the-market presumption applies (Nasdaq efficient market, high volume, analyst coverage). Loss causation: Corrective disclosures (e.g., Jan. 9, 2023 revenue miss tied to AviClear; Nov. 8, 2023 inventory shortfall/restatement need; Mar. 21, 2024 AviClear excess/returns) caused statistically significant stock drops (23%-42%), tracing to concealed risks. Economic loss follows. PSLRA safe harbor inapplicable (many historical facts, inadequate cautions, scienter). Motion denied; claim survives."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "§20(a) imposes control person liability where: (1) primary §10(b) violation; and (2) culpable participation (e.g., power to control primary violator + use of that power). Primary violation pled above. Individual Defendants (senior executives/directors signing filings, speaking on calls, certifying SOX) plausibly 'controlled' Cutera via high-level positions, direct involvement (e.g., Mowry/Plants directing AviClear focus per CWS/Special Committee), and dissemination authority. Culpable participation inferred from same scienter facts (motive, knowledge via CWS/reports, SOX lies). No 'special insulation' needed at pleading stage (Larkin); allegations suffice. Motion denied; claim survives."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 65508,
      "completion_tokens": 1188,
      "total_tokens": 67379
    },
    "case_id": "cand_23_cv_02560"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs Dr. Myo Thant (lead plaintiff) and Branden Schenkhuizen bring this securities class action on behalf of themselves and all persons who purchased Rain Oncology Inc. (f/k/a Rain Therapeutics Inc., 'Rain' or 'Company') common stock during the Class Period of April 23, 2021 (IPO date) to May 19, 2023 (inclusive), or whose purchases were pursuant or traceable to the IPO registration statement/prospectus. Defendants include Rain, Individual Defendants Avanish Vellanki (CEO/Chairman) and Richard Bryce (Executive VP/Chief Medical Officer), and Director Defendants Franklin Berger, Aaron Davis, Gorjan Hrustanovic, Tran Nguyen, Peter Radovich, and Stefani A. Wolff (board members who signed the IPO registration statement). The alleged misconduct centers on Defendants' misrepresentations and omissions regarding Rain's decision to bypass Phase 2 clinical trials ('Phase 2 Bypass') and advance directly to a pivotal Phase 3 trial (MANTRA) for its lead drug candidate milademetan (RAIN-32), an MDM2 inhibitor for well-differentiated/de-differentiated liposarcoma (WD/DD LPS). Rain licensed milademetan from Daiichi Sankyo in September 2020 based on Daiichi's Phase 1 trial (U101), which identified a recommended Phase 2 dose (260 mg intermittent) showing promising median progression-free survival (mPFS) of 7.4 months in a small LPS subgroup (n=16, ~15% of total 107 patients), but Daiichi planned a Phase 2. Key factual allegations: (1) Phase 1 data did not 'validate' dosing or support Phase 2 Bypass, as milademetan's mechanism/safety profile was not well-characterized (first-in-human, history of hematologic toxicities in MDM2 class); (2) Phase 2 Bypass was reckless gamble to save time/costs (~$11M+2 years), fundraise via IPO ($121.9M net proceeds), beat competitors; (3) Repeated false/misleading statements in IPO prospectus, SEC filings (10-Qs/10-Ks), press releases portraying Bypass as 'de-risked,' Phase 1 as validating dose, Company as 'late-stage,' misleading pipeline tables implying Rain conducted Phase 1/2; (4) Ignored SEC IPO review comments prohibiting such claims; (5) FE1 (former Senior Director) confirmed leaders (Vellanki/Bryce) knew data limitations, Bypass aggressive; (6) MANTRA initiated July 2021, failed May 22, 2023 (mPFS 3.6 vs. 2.2 months trabectedin control, HR 0.89 p=0.53 not significant; high Grade 3/4 toxicities suggesting poor dosing optimization), stock fell ~88% ($9.93 to $1.22); led to program halt, layoffs, Pathos AI acquisition. Claims: Count I (§10(b)/Rule 10b-5 vs. Rain/Vellanki/Bryce); Count II (§20(a) vs. Vellanki/Bryce); Count III (§11 Securities Act vs. Rain/Directors); Count IV (§15 vs. Directors). Plaintiffs allege artificial inflation, loss causation via corrective disclosures (Sept. 2021 Daiichi data, May 2023 failure), fraud-on-the-market reliance.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "dismissed",
          "reasoning": "To survive dismissal of a §10(b)/Rule 10b-5 claim under the PSLRA, plaintiffs must plead (1) material misrepresentation or omission, (2) scienter, (3) connection with purchase/sale of security, (4) reliance (presumed via fraud-on-the-market in efficient market), (5) economic loss, and (6) loss causation, with heightened particularity (Falsity: specific statements, why false; Scienter: strong inference of intent/recklessness). Here, alleged misstatements (e.g., Phase 1 'validated' dosing/supports Phase 3; 'late-stage' company; pipeline tables; Bypass as positive) are largely non-actionable opinions/puffery on clinical strategy or forward-looking (e.g., 'anticipate commencing Phase 3'), protected by PSLRA safe harbor as accompanied by robust risk disclosures in filings (generic clinical failure risks, though plaintiffs argue inadequate for atypical Bypass risk). No falsity: Phase 1 LPS subgroup (n=16) showed 3-4x mPFS improvement; Bypass not prohibited by FDA (IND clearance implied); competitors' paths irrelevant; SEC IPO comments addressed via revisions, post-IPO statements not 'ignored' as data unchanged. Pipeline tables source Phase 1 to Daiichi, show progress bars as planned. Scienter inference weak: FE1 alleges leaders 'understood limitations' but no contemporaneous knowledge of Phase 3 failure/dosing flaws (trial blinded/ongoing); no core operations doctrine flips burden (biotech trial design subjective); motive (fundraise) generic; Sarbox certs boilerplate. No strong competing negligence inference over recklessness. Loss causation: Partial disclosures (Sept. 2021, May 2023) show numerical PFS benefit (3.6>2.2), non-sig p-value/ high tox consistent with known MDM2 risks, not solely tied to Bypass. Dismissed without prejudice."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "dismissed",
          "reasoning": "Section 20(a) control person liability requires (1) primary §10(b) violation by controlled entity/person, and (2) culpable participation (control + direct/indirect influence over primary violator). No underlying §10(b) violation adequately pled (see Count I). Even if primary survived, control alleged (positions, signing filings) but no culpable participation beyond group pleading (insufficient post-Tellabs). Dismissed without prejudice."
        },
        {
          "claim": "Section 11 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Section 11 imposes strict liability/joint-and-several on issuers/signers for material misstatements/omissions in registration statement/prospectus; negligence standard (no scienter/ scienter-like pleading; plaintiffs disclaim fraud); standing for traceable IPO purchasers. Plaintiffs' Schenkhuizen has standing. Prospectus allegedly misstated Phase 1 'validated rationally-designed dosing schedule' supporting Phase 3 Bypass, omitting Bypass risks atypicality (small n=16 unexpanded, Daiichi Phase 2 plan, literature/industry warnings on non-characterized MoA/safety increasing Phase 3 failure odds), despite SEC comments flagging similar hype. Item 105 Reg S-K requires specific risk disclosure; generic trial failure warnings insufficient if Bypass posed outsized, undisclosed risk (FE1, studies cited). Directors signed; reasonable investigation duty (due diligence) plausibly breached given SEC exchanges copied to Vellanki/Doebele, FE1 warnings. Pipeline table arguably implies undue progress despite revisions. Materiality plausible (analyst reactions, stock drop post-failure). Economic loss pled. Sustained; discovery warranted on due diligence."
        },
        {
          "claim": "Section 15 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Section 15 control person liability mirrors §20(a) but for Securities Act primary (§11); requires (1) primary violation, (2) control (power to direct management/policies), (3) culpable participation (culpable state of mind, often negligence). Primary §11 survives (see Count III). Directors (signers) plausibly controlled contents (board oversight, signing duty); negligence via failure to investigate/revise post-SEC comments aligns with §11 theory. No heightened PSLRA pleading. Sustained."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 30892,
      "completion_tokens": 1663,
      "total_tokens": 34166
    },
    "case_id": "cand_23_cv_03518"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "This is a securities class action brought by lead plaintiffs (including Ken Kula) on behalf of all persons and entities who purchased or acquired Fastly, Inc. ('Fastly' or the 'Company') securities between November 15, 2023, and August 7, 2024 (the 'Class Period'), excluding defendants and related parties. Defendants are Fastly, a Delaware corporation providing an edge cloud platform including content delivery network (CDN) services; Todd Nightingale, CEO; and Ronald Kisling, CFO (collectively, 'Individual Defendants'). The complaint alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by making false and misleading statements and omissions regarding the impact of macroeconomic trends (e.g., rising interest rates), customer retention and expansion (particularly among enterprise and top 10 'big whale' customers like TikTok, Amazon Video, Apple, Twitter/X, Netflix, Paramount, Disney, which generated ~37% of FY 2023 revenue), and the company's focus on driving revenue growth from existing customers. Key factual allegations include: (i) reliance on seven detailed confidential witnesses (CWs 1-7, former sales, account management, program management, and website staff from 2021-2024) attesting to declining traffic/usage from large customers starting in 2023, contract cancellations (e.g., Indeed, USAA), aggressive discount demands correlated with macro pressures, sales quota misses (only 30% met in 2023), stagnant/stagnating growth, competitors catching up technologically; (ii) internal knowledge via quarterly 'all-hands' meetings (attended by C-suite and all employees, recordings distributed), where Nightingale discussed declining revenue/traffic from big customers 'throttling down' as early as November 2023; weekly Customer Ops meetings tracking customer traffic with red/yellow/green ratings and 'tiger teams' for poor performers; internal tools like Fastly App; post-Q1 2024 'war room'; (iii) 2024 shift to new sales compensation prioritizing new customer 'logos' (historically <10% of platform revenue), making existing customer focus 'punitive'; (iv) discontinuation of key metrics (DBNER, quarterly NRR) in Q1 2024; (v) insider sales by Nightingale (~410k shares for $5.97M) and Kisling (~150k shares for $1.97M) during Class Period. Specific challenged statements include November 15, 2023 conference denying macro headwinds; February 14, 2024 Q4/FY2023 earnings call and 10-K claiming stable retention, expansion from existing/enterprise customers, hypothetical risks (despite known declines); May 1, 2024 Q1 10-Q/earnings repeating focus on existing customers while omitting sales shift and lack of progress; partial corrective disclosures on February 14, 2024 (Q4 revenue miss, stock -30.6% to $16.34); May 1, 2024 (guidance cut blaming large customer declines/pricing/traffic, stock -32% to $8.79); August 7, 2024 (Q2 further declines, shift to new customers, top 10 share 40%→34%, stock -14.3% to $5.86), with analyst downgrades. Loss causation tied to these drops removing artificial inflation.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive a motion to dismiss a §10(b)/Rule 10b-5 claim under the PSLRA, the complaint must plead with particularity: (1) a material misrepresentation or omission, (2) scienter, (3) connection to a purchase/sale of securities, (4) reliance (presumed via fraud-on-the-market in efficient market like NYSE), (5) economic loss, and (6) loss causation. See Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005); Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007). Here, plaintiffs specify statements (e.g., ¶¶117-120 Nov. 2023 denial of macro effects; ¶¶125-127,130-133 Feb. 2024 earnings/10-K claims of stable retention/expansion; ¶¶168,173-174,176-179 May 2024 earnings/10-Q focus on existing customers) and explain falsity via detailed CW accounts (e.g., CW1/CW6 on Nightingale's internal Nov. 2023 admissions of big customer throttling/declines contradicting public denials), public metrics/revenue concentration (95% from platform usage, 37% top 10), contract cancellations/discounts, sales shift. Materiality is plausible given core business reliance on existing/large customers. Scienter (intentional/reckless conduct) is strongly pled: Nightingale's contradictory internal/public statements at all-hands (core operations inference heightened by CEO tracking top deals ¶196); multiple CWs (basis/timing/positions corroborated); weekly traffic tracking attended by execs; post-disclosure 'war room'; suspicious metric discontinuation timed to hide trends; substantial Class Period insider sales by both Individual Defendants (proceeds ~$7.9M total). Holistic Tellabs 'strong inference' overmatches non-culpable explanations. Reliance/loss causation presumed/efficient market; economic loss/stock drops (30-32%) tied to partial corrective disclosures revealing concealed facts (e.g., large customer declines). No safe harbor: many statements historical/current (e.g., 'stable retention'); forward-looking lacked meaningful cautionary language for known risks already materialized. Item 303 claim (trend disclosure) also viable as known unfavorable revenue trend from existing customers omitted. Pleads plausible primary violation against all defendants."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "Section 20(a) imposes control person liability on individuals who 'controlled' a primary violator with a §10(b) violation. Requires: (1) primary violation; (2) culpable participation (some wrongful act beyond mere status, e.g., recklessness); (3) 'control' (ability to influence management/policies). See 15 U.S.C. §78t(a); Parmalat Capital Fin. Corp. v. City of Milwaukee, 2011 WL 3418035 (N.D. Cal. Aug. 2, 2011). Primary §10(b) violation sustained above. Individual Defendants (CEO/CFO) plausibly 'controlled' Fastly: signed false/misleading 10-K/10-Q/SOX certs (¶¶136,172); controlled SEC filings/press/earnings content (¶47); Nightingale directly made statements, attended internal meetings. Culpable participation via scienter pled above (direct knowledge/recklessness). Sustained against Nightingale and Kisling."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 24939,
      "completion_tokens": 1496,
      "total_tokens": 27369
    },
    "case_id": "cand_24_cv_03170"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs are eight named individuals who were short sellers of Vicor Corporation's (NASDAQ: VICR) common stock: Daniel Pogrebinsky (CA), Benjamin Pouladian (CA), David Mead (WA), Aaron Goldman (NJ), Dr. Vijaykumar Agrawal (TN), Kent Maguire (KY), Timothy McKillican (Canada), and Zi Xu (UAE). Defendants are Vicor Corporation, a Delaware corporation headquartered in Massachusetts that designs and manufactures power components, and Patrizio Vinciarelli, its founder, President, CEO, and controlling shareholder. The complaint alleges that Vicor was struggling in 2023 with declining revenues, shrinking backlog (down ~47% YoY), and loss of major customers Nvidia and Google. On July 25, 2023, during its Q2 earnings release and conference call, Vinciarelli stated that Vicor had entered a new agreement with a 'significant existing customer' for its next-generation 4G lateral power distribution design, expected to ramp deliveries in Q4 2023, including specifics like 1,000 amp level and lateral-then-lateral-vertical implementations. This caused Vicor's stock to surge from $59 (July 25 close) to $93.70 (July 26 close, intraday high >$94), with volume spiking to 4.5M shares (5-6x normal). Plaintiffs, who had shorted starting ~May 2023, were allegedly forced to cover at inflated prices (~$35/share loss plus lost gains). On October 24, 2023 Q3 call, Defendants omitted updates, dodged analyst questions about the customer, denied specificity, and pivoted to 'medium to long term' growth from new unidentified customers, causing stock to drop ~20% overnight to $39 (high volume again). A September 3, 2024 press release claimed $30M in non-cancellable/non-returnable bookings reflecting the customer's 'allocation,' which Plaintiffs call a cover-up as no 8-K was filed and no breach suit pursued. Plaintiffs seek class certification for short sellers who opened positions prior to/on July 25, 2023, and covered in days following including October 24, 2023 ('Class Period'). Claims: Count One - Violations of §10(b) of the Securities Exchange Act of 1934 and Rule 10b-5(b) against all Defendants (misrepresentations/omissions of material fact re: customer deal, scienter, reliance via efficient market, loss causation, damages); Count Two - Violations of §20(a) against Vinciarelli (control person liability).",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5(b)",
          "ruling": "dismissed",
          "reasoning": "To survive dismissal under Fed. R. Civ. P. 12(b)(6) and the PSLRA, 15 U.S.C. § 78u-4(b), the complaint must plead: (1) a material misrepresentation or omission, (2) scienter, (3) in connection with purchase/sale of securities, (4) reliance, (5) economic loss, and (6) loss causation, with falsity and scienter pled with particularity and scienter raising a 'strong inference' plausible only on a reasonable person's view that defendants acted with knowledge or recklessness. See Dura Pharms. Inc. v. Broudo, 544 U.S. 336 (2005); Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007); Ashcroft v. Iqbal, 556 U.S. 662 (2009). The July 25, 2023 statements ('existing customer,' 'significant customer,' 'expected to ramp in Q4') are forward-looking opinions about anticipated production/release/ramp for a new AI platform, couched amid admissions of 'weak' Q2 bookings and prior struggles—not guarantees of firm contracts or deliveries. No particular facts show falsity when made: no confidential witnesses, customer denials, or documents contradict; the September 2024 press release (post-suit) affirms $30M NCNR bookings based on customer's program allocation, consistent with an 'existing significant customer' expectation. October 24 dodges ('not going to talk about any one customer,' pivot to diversification) reflect competitive nondisclosure, not admissions of falsity, and lack materiality as they do not affirm/deny a Q4 ramp but emphasize 'medium/long term.' Market reactions (spikes/drops) show sensitivity but not materiality absent falsity. Scienter fails: core operations inference weak given forward nature and Vicor's access to contrary facts unpled; motives (Vunciarelli's ownership, ~$350M paper gain, $1M insider sales, anti-short squeeze) are generic/self-interested, not 'unusual' executive compensation (Tellabs); no SARs-like temporal proximity to sales; cover-up theory implausible as press release supports truthfulness. Reliance via fraud-on-the-market presumes efficiency for covering purchases, but shorts' 'forced cover' allegation is conclusory, and class definition mismatches named plaintiffs' timeline (covered post-7/26, not post-10/24). Loss causation absent: no corrective disclosure revealed truth (stock drop tied to no update amid weak results, not fraud revelation); shorts' damages (cover costs + lost drop gains) not proximately linked as inflation dissipated pre-cover for some. Claim dismissed without prejudice."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "dismissed",
          "reasoning": "Section 20(a) requires a primary violation (e.g., §10(b)) and culpable participation by a controlling person with power to direct/directing management/policies. See 15 U.S.C. § 78t(a); Par+fRMS Fund, Inc. v. Dendler, 803 F.3d 1 (1st Cir. 2015). Absent a viable primary §10(b) claim, §20(a) fails. Even if primary survived, control adequately pled (Vunciarelli as CEO signing disclosures, 'effective control' via voting stock), but 'culpable participation' requires knowing/reckless conduct mirroring §10(b) scienter, which fails here for same reasons. Dismissed without prejudice."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 11779,
      "completion_tokens": 1329,
      "total_tokens": 15393
    },
    "case_id": "cand_24_cv_04196"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs Vinod Sodha and Amee Sodha, on behalf of a proposed class of all persons and entities that acquired Robinhood Markets, Inc. ('Robinhood' or 'Company') common stock pursuant or traceable to the Company's initial public offering ('IPO' or 'Offering') on July 30, 2021 (effective July 28, 2021), allege violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933. Defendants include: (1) Robinhood, a financial services platform offering commission-free brokerage via mobile app, known for 'democratizing' finance; (2) Individual Defendants, senior executives and directors who signed the Registration Statement--CEO Vladimir Tenev, CFO Jason Warnick, Chief Creative Officer Baiju Bhatt, and Directors Jan Hammer, Paula Loop, Jonathan Rubenstein, Scott Sandell, and Robert Zoellick; and (3) Underwriter Defendants, including Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Barclays Capital Inc., Wells Fargo Securities, LLC, Mizuho Securities USA LLC, JMP Securities LLC, KeyBanc Capital Markets Inc., Piper Sandler & Co., Rosenblatt Securities Inc., BMO Capital Markets Corp., BTIG, LLC, Santander Investment Securities Inc., Academy Securities, Inc., Loop Capital Markets LLC, Samuel A. Ramirez & Company, Inc., Siebert Williams Shank & Co., LLC, and Citigroup Global Markets Inc., who underwrote the IPO of 55 million shares at $38 per share, raising over $2 billion. The alleged misconduct consists of material false and misleading statements and omissions in the Offering Documents (Registration Statement and Prospectus), which touted Robinhood's successful execution of a customer-centric, safety-first strategy focused on platform reliability, small investors' needs, rapid response to feedback, and bold innovation, driving exponential growth in key performance indicators ('KPIs') like Monthly Active Users ('MAU'; projected 21.3 million for Q2 2021), Assets Under Custody ('AUC'; projected $102 billion), Net Cumulative Funded Accounts ('NCFA'; projected 22.5 million), Average Revenue Per User ('ARPU'; $137 in Q1 2021), and revenue/crypto trading volumes. These claims were contradicted by undisclosed facts known pre-IPO: (i) operational failures, including rampant fraud due to inadequate controls/personnel (backlogs, no automation, hard-to-close accounts), platform outages/disruptions, poor customer service/training, gamification features (e.g., blinking dot, confetti) inducing frequent/risky trading (options/margin for novices despite losses), customer attrition, declining Net Promoter Score ('NPS'), and employee warnings ignored by executives; (ii) sharp KPI/revenue declines in May-July 2021 (MAU down 11.62% May-June, 8.45% June-July, losing 4.6 million users; crypto volume down 76% May-June, 56.67% June-July, losing $114 billion; AUC down 4.25%; NCFA stagnant; ARPU down $25+), tracked in real-time via internal analytics (Looker dashboards) and discussed at executive meetings. Supported by five confidential witnesses (former employees/contractors) confirming internal knowledge. Risk factors deemed inadequate/misleading; violations of SEC Items 303 (known trends impacting revenues) and 105 (risk disclosure). Truth emerged post-IPO via Q3 2021 earnings (Oct. 27, 2021; MAU 18.9M, revenue/crypto down sharply), data breaches, regulatory scrutiny, analyst/media criticism, causing stock to plummet ~82% to $6.81 low. Legal claims: (1) §11 against all Defendants (strict liability for Offering Documents' misstatements/omissions); (2) §12(a)(2) against all Defendants (untrue Prospectus statements in traced sales/offers); (3) §15 against Individual Defendants (control person liability). The 'class period' is limited to acquisitions pursuant/traceable to the Offering; significant dates include S-1 filing (July 1, 2021), effectiveness (July 28, 2021), IPO pricing (July 30, 2021), and partial corrections October 2021 onward.",
      "claim_rulings": [
        {
          "claim": "Section 11 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Section 11 imposes strict liability on issuers, signing officers/directors, and underwriters for material misstatements or omissions in a registration statement, or failures to state facts necessary to make statements not misleading, without regard to scienter, reliance, or loss causation; plaintiffs need only identify specific statements, allege falsity, and plead materiality (reasonable investor's likelihood of viewing as significantly altering total mix of information). Here, the complaint satisfies this standard by quoting precise statements from the Offering Documents (e.g., ¶¶141-145 touting strategy execution, customer trust/safety, platform reliability; ¶¶149-152/150-151 KPI tables/estimates depicting historical/projected growth through Q2 2021; misleading risk factors downplaying realized risks like declines/outages/fraud), explaining falsity with particularity via CW accounts of internal operations contradicting claims (e.g., ignored fraud controls, gamification prioritizing revenue over customers, executive knowledge of attrition/NPS declines), real-time metric tracking showing pre-IPO deteriorations (e.g., MAU/crypto drops contradicting growth narrative), and later-revealed monthly data confirming trends. Materiality is plausibly alleged via stock price declines post-disclosures (e.g., 10%+ drop after Q3 earnings), analyst/media reactions emphasizing surprises. Generalized/puffing statements (e.g., 'revolutionary') may be non-actionable, but KPI data are factual/historical, intra-quarter trends/omissions arguably required under Item 303 (known unfavorable revenue-impacting trends), and risk factors inadequate under Item 105 as they obscured actualized/current risks rather than hypotheticals. Forward-looking safe harbor inapplicable to historical/mixed statements lacking meaningful cautionary language tied to risks. Underwriters' due diligence is affirmative defense not resolvable on motion to dismiss. Complaint disclaims fraud; allegations suffice under Iqbal/Twombly to state plausible claim against all defendants."
        },
        {
          "claim": "Section 12(a)(2) of the Securities Act",
          "ruling": "dismissed_in_part",
          "reasoning": "Section 12(a)(2) provides rescissionary relief against any person who offers or sells a security via a prospectus containing material untrue statements/omissions (or fails to state necessary facts), but only against 'statutory sellers' who either (1) pass title or (2) actively solicit offers with intent to sell (prospectus traceable to their efforts); no scienter or due diligence required at pleading stage, mirroring §11 standards for materiality/falsity. Motion granted as to Individual Defendants (dismissed), who are not alleged to have directly passed title, solicited purchases, or sold shares (liability requires more than signing/control; passive signers/reviewers insufficient per controlling precedent like Pinter v. Dahl). Motion denied as to Robinhood (issuer offering via Prospectus) and Underwriter Defendants (active solicitors who allocated shares, conducted roadshows, disseminated Documents for financial gain, passing title). Against these, same actionable misstatements/omissions as §11 plausibly pled (KPI growth claims false amid known declines, strategy boasts contradicted by CWs/operations); traceability presumed for IPO class; post-sale plaintiffs may elect damages. Survives 12(b)(6)."
        },
        {
          "claim": "Section 15 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Section 15 imposes joint/several control person liability for §11/§12(a)(2) primary violations, requiring: (1) primary violation; (2) control (power/ability to control primary violator's conduct, via board/executive position); and (3) culpable participation (culpable state of mind plus action furthering violation). Primary §11 claim survives (basis for §12 too); Individual Defendants plausibly controlled as senior executives/directors (CEO/CFO/CCO with operational oversight, signing directors approving Documents). Culpability adequately pled via signing/review/approval of Documents (direct participation), CW allegations of executive meeting discussions ignoring declines/warnings (e.g., Tenev/Bhatt/Warnick aware of metrics/attrition via dashboards/all-hands), power to influence disclosures. Pre-discovery, signing high-position suffices; no heightened scienter pleading needed. Motion denied."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 29539,
      "completion_tokens": 1803,
      "total_tokens": 33991
    },
    "case_id": "cand_3_21-cv-09767"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "The Lead Plaintiff, Steamfitters Local 449 Pension & Retirement Security Funds, brings this securities class action individually and on behalf of all persons and entities who purchased or otherwise acquired SunPower Corporation ('SunPower' or the 'Company') publicly traded securities (NASDAQ: SPWR) during the Class Period from August 3, 2021, through January 20, 2022, inclusive, and were damaged thereby. Defendants are SunPower, a Delaware corporation headquartered in San Jose, California, and majority-owned by TotalEnergies; Peter Faricy, SunPower's CEO, President, and Chairman of the Board during the Class Period; and Manavendra S. Sial, SunPower's former CFO and Executive Vice President. SunPower is a solar energy company focused on distributed generation residential (RLC) and commercial (CIS/C&I, including light commercial CVAR) markets, relying on third-party suppliers like Maxeon for panels. The alleged fraudulent conduct involves Defendants' material misrepresentations and omissions in press releases, earnings calls, investor presentations, and SEC filings (Forms 10-Q for 2Q21 and 3Q21) regarding: (i) the strength, trajectory, margin performance, and balance sheet health of SunPower's commercial business; (ii) the Company being 'on track' to meet FY21 financial guidance (revenue $1.41-$1.49B, Adjusted EBITDA $110-$130M); and (iii) risks of product defects, misleadingly framed as hypothetical 'if' risks despite actual, pervasive cracking defects in third-party factory-installed connectors affecting nearly all commercial systems installed since 2019. Key factual allegations include: touting 'solid execution' and improved CIS margins on August 3, 2021 (2Q21 earnings); affirming CIS as 'very healthy' and a 'point of strength' on October 5, 2021, while exploring strategic options (sale) for CIS; claiming 'healthiest balance sheet in years' on November 3, 2021 (3Q21 earnings); boilerplate 10-Q risk factors warning of potential future defects; December 7, 2021 update to installation manual adding specific cracking warnings (absent prior); and January 20, 2022 preannouncement revealing the cracking issue 'developed over time,' $27M 4Q21 and $4M 1Q22 supplier-quality charges for proactive replacements across CVAR and CIS, lowered EBITDA guidance, hiring new supply chain exec, and advanced CIS sale talks—causing SPWR stock to drop 16.9% from $19.02 to $15.80 on heavy volume. Plaintiff alleges Defendants knew or recklessly disregarded these facts due to executive access, core business importance, product quality assessments, and CIS sale due diligence, artificially inflating stock to $34.61. Analyst reports post-disclosure noted pervasiveness ('nearly all' systems), likely discovery in due diligence, and retrofit needs (~1,000 sites, 9MW). Legal claims: Count I - Violations of §10(b) of the Exchange Act and Rule 10b-5 against all Defendants; Count II - Violations of §20(a) of the Exchange Act (control person liability) against all Defendants. Significant dates: August 3, 2021 (Class Period start, 2Q21 earnings); October 5, 2021 (CIS strategic review); November 3, 2021 (3Q21 earnings); December 7, 2021 (manual update); January 20, 2022 (corrective disclosure, Class Period end); February 2022 (CIS sale).",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal of a §10(b) and Rule 10b-5 claim under the PSLRA, the complaint must plead: (1) a material misrepresentation or omission, (2) scienter, (3) connection to a purchase or sale, (4) reliance, (5) economic loss, and (6) loss causation, with heightened particularity (F.R.C.P. 9(b); 15 U.S.C. §78u-4(b)) and facts supporting a 'strong inference' of scienter (Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007)). Here, the complaint satisfies each element plausibly under Iqbal/Twombly. Material misrepresentations/omissions are particularized in ¶¶38-70, identifying specific statements (e.g., Faricy's August 3 PR quotes on 'solid execution' and 'on track'; Sial's call claims of CIS 'significantly better' margins and profitability; October/November touts of CIS as 'healthy'/'point of strength'; 'healthiest balance sheet'; FY21 guidance affirmations) and Forms 10-Q risk factors misleadingly positing hypothetical 'if' defects despite known present/pervasive cracking in connectors affecting 'nearly all' commercial systems since 2019 (¶¶15, 50, 67). Falsity is pled via January 20 disclosure confirming issue 'developed over time,' $31M charges, and lowered guidance (¶20), corroborated by analysts (Roth: 'nearly all C&I systems since 2019'; Cowen/Truist: likely due diligence discovery). These were material as commercial was ~25% revenue, key differentiator. Scienter is strongly inferred holistically: Individual Defendants' senior roles (CEO/CFO signing filings, controlling content, ¶¶32-36) gave access to adverse facts in core commercial operations; timing aligns with CIS sale process (advanced DD implying knowledge, ¶¶12, 22); December 7 manual update adds cracking warnings; no contrary inference (e.g., recent 'quality assessment' suggests pre-disclosure awareness); motive unnecessary but present (facilitate CIS sale). Reliance presumed via fraud-on-the-market (Basic Inc. v. Levinson, 485 U.S. 224 (1988)) in efficient NASDAQ market. Economic loss and loss causation pled via 16.9% stock drop ($19.02 to $15.80) on January 21 tied directly to disclosure (high volume, analyst reactions distinguishing from weather/COVID, ¶¶22, 92). No safe harbor for non-forward-looking statements or known-false projections (¶¶93-94). Claims against all Defendants (scheme liability, ¶37). Motion denied."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "Section 20(a) imposes control person liability for underlying §10(b) violations upon showing: (1) a primary violation of the securities laws, and (2) that the defendant 'controlled' the primary violator (Parmalat Capital Fin. Ltd. v. Bank of Am. Corp., 671 F.3d 261 (2d Cir. 2012); 15 U.S.C. §78t(a)). Control requires 'the power to direct or cause the direction of the management and policies' of the primary violator, typically pled via status (officer/director) plus culpable participation or specific facts (e.g., signing false filings, making statements) (Howard v. Everex Sys., Inc., 228 F.3d 1057 (9th Cir. 2000)). Here, primary §10(b) violation adequately pled (see above). Individual Defendants qualify as controlling persons: Faricy (CEO/President/Chairman, ¶32) and Sial (CFO/EVP, ¶33) held ultimate authority, participated directly (hosted calls, quoted in PRs, signed 10-Qs/SOX certs, ¶¶34-36), and controlled content disseminated. SunPower controlled them as employer. No heightened scienter required beyond primary claim (Larkin v. GlaxoSmithKline, 2013 WL 5863025 (N.D. Cal. 2013)). Motion denied as to all Defendants."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 20229,
      "completion_tokens": 1704,
      "total_tokens": 23560
    },
    "case_id": "cand_3_22-cv-00956"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Lead Plaintiff Dipak Patel, on behalf of a class of all persons and entities who purchased or acquired ImmunityBio, Inc. (IBRX) securities between March 10, 2021, and May 10, 2023 (Class Period), brings this securities fraud action against ImmunityBio (a clinical-stage biopharmaceutical company focused on immunotherapies, particularly lead candidate Anktiva (N-803) for bladder cancer) and Individual Defendants: Patrick Soon-Shiong (Executive Chairman and Global Chief Scientific and Medical Officer), Richard Adcock (CEO), and David C. Sachs (CFO). The alleged misconduct involves Defendants' materially false and misleading statements and omissions in SEC filings (e.g., Forms 10-K, 10-Q, 8-K, S-3), press releases, and prospectuses claiming the Company had 'established GMP [cGMP] manufacturing capacity at scale,' 'cGMP-compliant facilities,' and 'robust process development and validation and quality oversight' at third-party CMO AGC Biologics (where Anktiva's active ingredient was manufactured), while omitting known, serious, recurring cGMP violations at AGC. Key factual allegations: FDA issued Form 483s to AGC in March 2021 (16 observations) and July 2021 (3 observations) for failures in deviation investigations, documentation, sanitation, etc.; ongoing issues (delayed batch releases/dispositions, untimely deviation investigations/CAPAs, missed stability tests, reference material shortages, multiple failed PPQ batches for Anktiva); ImmunityBio executives (Adcock, Sender) held frequent meetings with AGC; Quality Agreement required AGC to report deviations/inspections to ImmunityBio; CW1-CW4 (former ImmunityBio/AGC employees) confirm Defendants' knowledge; mock inspection (Jan. 2023) revealed issues; FDA pre-license inspection (Feb. 2023) issued 15-page, 5-item Form 483 (OAI classification) for systemic cGMP failures (e.g., deviation management, data integrity, contamination risks, quality oversight lapses); similar issues at fill/finish CMO; BLA submitted May 23, 2022 (accepted July 2022, PDUFA May 23, 2023); CRL issued May 9, 2023 (announced May 11, 2023) citing CMO inspection deficiencies (not clinical data), causing 55% stock drop. Expert (Todd Clark) opines violations grave, warranting BLA withhold. Claims: Count I (Section 10(b)/Rule 10b-5 against all Defendants); Count II (Section 20(a) control person liability against Individuals). Scienter inferred from core business centrality (Anktiva only path to revenue), executive involvement (meetings, real-time inspection updates, Soon-Shiong's BLA review), CWs, in-house manufacturing plans. Loss causation via stock crash; reliance via fraud-on-the-market.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and SEC Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under PSLRA (15 U.S.C. § 78u-4(b)), complaint must plead (1) material misrepresentation/omission, (2) scienter, (3) connection with purchase/sale of security in efficient market (Basic, 485 U.S. 224 (1988)), (4) reliance, (5) economic loss, and (6) loss causation (Dura Pharms., 544 U.S. 336 (2005)), with particularity (no fraud-by-hindsight, puffery, or protected forward-looking statements). Here, particularized allegations satisfy all elements. Material misrepresentations/omissions: Complaint quotes ~30 specific statements (e.g., 'established GMP manufacturing capacity at scale'; 'cGMP-compliant facilities'; 'robust...quality oversight') in Forms 10-K/Q/S-3, 8-Ks, press releases, signed by Individuals, falsely implying Company/CMO cGMP compliance/readiness when Defendants knew of AGC's repeated violations (March/July 2021 Form 483s, delays in batches/deviations/stability, failed PPQs, OAI inspection). Risks disclosures misleading as omitting actual, known problems (Matrixx Initiatives, 563 U.S. 27 (2011)); statements verifiable/not puffery given specificity/context (Anktiva BLA imminent). Materiality: Anktiva Company's only near-term revenue source; analysts/market assumed no mfg. issues pre-CRL. Scienter: Strong inference of intent/recklessness via holistic Tellabs (551 U.S. 308 (2007)) analysis—core operations doctrine (success hinged on Anktiva BLA); CW1-4 detail executives' knowledge (Adcock/Sender bi-monthly meetings on delays; Soon-Shiong demanded daily inspection calls, flew Adcock, reviewed BLA; 'pre-approval tracker' spreadsheet); Quality Agreement mandated AGC reports; mock inspection findings briefed to leadership; in-house shift plans; no motive needed. Outweighs non-scienter inferences. Reliance/loss causation: Efficient market (NASDAQ, high volume/analyst coverage); fraud-on-market presumption; 55% stock drop ($3.43/share, heavy volume) on May 11, 2023 partial corrective disclosure (CRL citing CMO deficiencies), negating confounding factors. PSLRA safe harbor inapplicable: Many present-tense/historical; warnings identical/generic despite known risks (not meaningful). Claims plausibly state §10(b)/10b-5 against all Defendants; motion denied."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "Section 20(a) (15 U.S.C. § 78t(a)) imposes control person liability for underlying §10(b) primary violation if 'culpable participation' (Parmalat, 414 F. Supp. 2d 331 (S.D.N.Y. 2006)) or power to control + actual control (Howard v. Everex, 228 F.3d 1057 (9th Cir. 2000)). Primary §10(b) violation sustained above. Individuals (Soon-Shiong, Adcock, Sachs) culpable: Senior officers/directors signed false filings/press releases; Adcock/Soon-Shiong directly involved (meetings, inspections, BLA review); Sachs signed 10-Qs/8-Ks; 'direct and supervisory involvement' in operations/disclosures alleged. Power/control via positions (CEO/CFO/Exec Chair), signing authority, imputed Company knowledge. PSLRA particularity met via same facts as primary claim. Motion denied as to Individuals."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 33087,
      "completion_tokens": 1402,
      "total_tokens": 35488
    },
    "case_id": "casd_3_23-cv-01216"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs: The Securities and Exchange Commission (SEC). Defendants: Lovesac Company (a Delaware corporation and Nasdaq-listed furniture retailer trading as 'LOVE'), Donna Dellomo (former CFO and EVP), and Yoon Um (former Controller and VP). Alleged fraudulent conduct: Dellomo and Um, both CPAs, engaged in a scheme to improperly capitalize approximately $2.2 million in 'last mile' shipping expenses incurred in FY 2023 Q4 but recorded in FY 2024 Q1, violating GAAP as these expenses provided no future economic benefit. This was done to meet Lovesac's publicly disclosed 50.1% gross margin projection for Q1 FY 2024 and avoid restating FY 2023 financials. Um booked the fraudulent journal entry on April 26, 2023, approved by Dellomo on April 27, 2023, without supporting documentation or materiality analysis. Dellomo falsely certified the Q1 FY 2024 Form 10-Q, submitted misleading management representation letters to auditors, and failed to disclose the issue. Lovesac failed to maintain adequate internal controls over financial reporting (ICFR). Key factual allegations: Internal chats/emails show awareness of impropriety (e.g., Um stated she 'could not justify' and felt 'not comfortable'), motive (meet guidance, job security), GAAP violation (shipping expenses must be expensed when incurred per company disclosures), and impact on filings. Resulted in materially misleading SEC filings: FY 2023 Form 8-K (3/28/2023) and 10-K (3/29/2023); Q1 FY 2024 Form 8-K (6/7/2023) and 10-Q (6/9/2023). Lovesac announced non-reliance and restated on 8/16/2023 via Form 8-K. Securities context: Ongoing trading, Form S-8 for stock compensation, warrant exercises (6/26/2023). Legal claims: Fifteen causes of action under Securities Act §17(a) and Exchange Act §§10(b), 13(a)/(b)(2)/(b)(5) and related rules for fraud, false filings, books/records violations, ICFR failures, false certifications, and aiding/abetting. No defined class period (SEC enforcement action, not private class action), but relevant period spans FY 2023 (ended 1/29/2023) and Q1 FY 2024, with key events April 2023.",
      "claim_rulings": [
        {
          "claim": "Securities Act Sections 17(a)(1) and 17(a)(3) against Dellomo and Um",
          "ruling": "sustained",
          "reasoning": "To state a claim under §17(a)(1), SEC must plead a scheme to defraud with scienter; under §17(a)(3), negligent or reckless fraudulent practices in offer/sale of securities. Accepting facts as true, complaint plausibly alleges Dellomo and Um knowingly/recklessly devised and executed a scheme (improper capitalization/journal entry) rendering filings misleading, connected to securities offerings/sales (S-8, warrants, trading), using interstate commerce. Internal communications evidence scienter (knowledge of GAAP violation, inability to justify); misstatements material (restatement); no scienter bar under Iqbal as motive, professional expertise, and doubts suffice. Motion denied."
        },
        {
          "claim": "Securities Act Section 17(a)(3) against Lovesac",
          "ruling": "sustained",
          "reasoning": "§17(a)(3) requires negligent practices operating as fraud in offer/sale. Complaint pleads Lovesac filed misleading reports due to defendants' misconduct, without adequate ICFR, connected to offerings/sales. Negligence standard met by failure to detect/implement controls; materiality via restatement. No heightened scienter needed. Motion denied."
        },
        {
          "claim": "Exchange Act Section 10(b) and Rules 10b-5(a) and (c) against Dellomo and Um",
          "ruling": "sustained",
          "reasoning": "SEC §10(b)/10b-5(a),(c) claims require material misrepresentation/omission (or scheme), scienter, connection to purchase/sale, interstate commerce (no private reliance/loss causation needed). Scheme (fraudulent journal entry hiding expenses) rendered filings misleading; scienter via CPA knowledge, chats admitting impropriety, motive; material (impacted gross margins, restated); connection via public filings influencing trades/S-8/warrants. Plausibly pled. Motion denied."
        },
        {
          "claim": "Exchange Act Section 10(b) and Rule 10b-5(b) against Dellomo",
          "ruling": "sustained",
          "reasoning": "Requires material misstatement/omission, scienter, connection to purchase/sale. Dellomo's false certification of Q1 10-Q, approval of entry, and oversight of filings constitute omissions (no disclosure of manipulation/ICFR weakness); scienter as above; material and connected. Motion denied."
        },
        {
          "claim": "Aiding and Abetting Dellomo’s Exchange Act Section 10(b) and Rule 10b-5(b) against Um",
          "ruling": "sustained",
          "reasoning": "§20(e) aiding/abetting requires primary violation (pled), knowing substantial assistance. Um's journal entry directly caused misstatements, with knowledge/recklessness (chats, GAAP expertise). Concert with Dellomo pled. Motion denied."
        },
        {
          "claim": "Exchange Act Section 13(b)(5) against Dellomo",
          "ruling": "sustained",
          "reasoning": "§13(b)(5) prohibits knowing circumvention/failure of ICFR or falsification of books. Dellomo knowingly approved non-GAAP entry, failed to implement controls, misled auditors/certs. 'Knowing' scienter met by facts. Motion denied."
        },
        {
          "claim": "Exchange Act Rule 13b2-1 against Dellomo and Um",
          "ruling": "sustained",
          "reasoning": "Rule 13b2-1 strictly prohibits falsifying books/records (no scienter required). $2.2M capitalization improperly reflected expenses as asset, falsifying ledger. Restatement confirms inaccuracy. Motion denied."
        },
        {
          "claim": "Exchange Act Rule 13b2-2 against Dellomo",
          "ruling": "sustained",
          "reasoning": "Prohibits misleading accountants re: audits/filings. Dellomo's false management letter (e.g., GAAP conformity, no unrecorded transactions) and omission of entry/issue to auditors knowingly omitted material facts. Motion denied."
        },
        {
          "claim": "Exchange Act Section 13(a) and Rules 12b-20, 13a-1, 13a-11, 13a-13 against Lovesac",
          "ruling": "sustained",
          "reasoning": "Requires accurate periodic reports, plus material info to avoid misleading. Specified filings omitted out-of-period expenses, GAAP non-compliance, ICFR weaknesses; material per restatement. Strict liability for issuer. Motion denied."
        },
        {
          "claim": "Aiding and Abetting Lovesac’s Exchange Act Section 13(a) and Rules 12b-20, 13a-1, 13a-11, 13a-13 against Dellomo and Um",
          "ruling": "sustained",
          "reasoning": "Primary violation pled; defendants knowingly provided substantial assistance via entry, approvals, certifications causing false filings. Motion denied."
        },
        {
          "claim": "Exchange Act Rule 13a-14 against Dellomo",
          "ruling": "sustained",
          "reasoning": "Sarbanes-Oxley certification must be accurate. Dellomo certified Q1 10-Q as GAAP-compliant/fairly presenting, disclosing deficiencies/fraud, knowing falsity from entry/ICFR failure. Motion denied."
        },
        {
          "claim": "Exchange Act Section 13(b)(2)(A) against Lovesac",
          "ruling": "sustained",
          "reasoning": "Requires books/records accurately reflect transactions 'in reasonable detail.' Ledger improperly capitalized expenses; restatement shows inaccuracy. Strict for issuers. Motion denied."
        },
        {
          "claim": "Aiding and Abetting Lovesac’s Exchange Act Section 13(b)(2)(A) against Dellomo and Um",
          "ruling": "sustained",
          "reasoning": "Primary pled; knowing substantial assistance via falsifying entry. Motion denied."
        },
        {
          "claim": "Exchange Act Section 13(b)(2)(B) against Lovesac",
          "ruling": "sustained",
          "reasoning": "Requires ICFR providing reasonable assurance of GAAP compliance. No accrual controls, journal oversight led to undetected fraud/restatement. Motion denied."
        },
        {
          "claim": "Aiding and Abetting Lovesac’s Exchange Act Section 13(b)(2)(B) against Dellomo",
          "ruling": "sustained",
          "reasoning": "Primary pled (note: body references Um, but header limits to Dellomo); Dellomo as CFO knowingly failed to implement/promote controls, approved fraud. Sufficient assistance. Motion denied."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 12053,
      "completion_tokens": 1987,
      "total_tokens": 16656
    },
    "case_id": "ctd-3_24-cv-01727"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "The plaintiff is the U.S. Securities and Exchange Commission (SEC). Defendants are Binance Holdings Limited (Binance, operator of Binance.com), BAM Trading Services Inc. (operator of Binance.US), BAM Management US Holdings Inc. (parent of BAM Trading), and Changpeng Zhao (CZ, founder, CEO, and controlling person of Binance and BAM entities). The alleged misconduct involves Defendants operating unregistered national securities exchanges, broker-dealers, and clearing agencies on the Binance Platforms while offering and trading numerous crypto asset securities (including BNB, BUSD, SOL, ADA, MATIC, FIL, ATOM, SAND, MANA, ALGO, AXS, COTI); conducting unregistered public offers and sales of crypto asset securities such as BNB, BUSD, Simple Earn, BNB Vault (Binance), and Staking Program (BAM Trading); and BAM Trading/BAM Management making material misrepresentations and engaging in deceptive practices regarding trade surveillance and controls on Binance.US, allowing undisclosed wash trading by Zhao-controlled Sigma Chain that inflated volumes. Key factual allegations include: Zhao's 'Tai Chi Plan' to evade U.S. registration via BAM entities while retaining control (e.g., custody of assets, matching engine, data access until recently); commingling and diverting U.S. customer funds through Zhao entities like Merit Peak/Sigma Chain; covert solicitation/retention of U.S. users on Binance.com post-2019 via VPN/KYC circumvention; failure to implement surveillance despite claims, enabling Sigma Chain wash trading (e.g., 99% of initial volume in some assets); crypto assets qualify as securities under Howey due to common enterprise, efforts of others, profit expectations from promoters' development/marketing. Legal claims: 13 causes of action under Securities Act §§5(a)/(c) (unregistered offers/sales), Exchange Act §§5/15(a)/17A(b) (unregistered exchange/broker/clearing), §20(a) control liability (Zhao), and Securities Act §17(a)(2)/(3) (fraud/misrep). No class period specified (SEC enforcement action, not class action); significant dates: Binance.com launch/BNB ICO (July 2017), Binance.US launch (Sep. 2019), ongoing to present (2023). SEC seeks injunctions, disgorgement, penalties, conduct bars.",
      "claim_rulings": [
        {
          "claim": "Securities Act Sections 5(a) and 5(c) (Against Binance for Unregistered Offers and Sales of BNB)",
          "ruling": "sustained",
          "reasoning": "Sections 5(a) and 5(c) impose strict liability for unregistered offers/sales of securities via interstate commerce without exemption. Complaint plausibly alleges BNB is a security under Howey (investment of money in common enterprise with expectation of profits from managerial efforts): ICO raised $15M tied to Binance.com success, whitepaper/marketing emphasized team expertise/platform growth, burns/dividends-like mechanics, ongoing promotions (e.g., discounts, ecosystem grants). No registration/exemption pled; U.S. nexus via open sales, U.S. purchasers, platforms. Detailed facts (whitepaper quotes, Zhao statements, trading data) satisfy Iqbal/Twombly; motion denied."
        },
        {
          "claim": "Securities Act Sections 5(a) and 5(c) (Against Binance for Unregistered Offers and Sales of BUSD)",
          "ruling": "sustained",
          "reasoning": "Strict liability under §§5(a)/(c). BUSD plausibly a security: stablecoin backed by pooled reserves invested for yield (50/50 split with Trust Co. A), marketed for APY/profit programs (Earn, staking ~2-30%), common enterprise via ecosystem returns. Unregistered public sales to U.S. users on platforms; no exemption. Facts (BUSD Agreement, promotions, $16B circulation, 90% on Binance) adequate; survives dismissal."
        },
        {
          "claim": "Securities Act Sections 5(a) and 5(c) (Against Binance for Unregistered Offers and Sales of Simple Earn and BNB Vault)",
          "ruling": "sustained",
          "reasoning": "Strict liability applies. Programs are investment contracts: pooled assets deployed by Binance expertise (staking/loans/Launchpool), variable APYs (up to 18.9%), pro rata returns; U.S. participation (3K-16K users). No registration; interstate promotion/sales. Well-pled (marketing, mechanics, volumes); claim survives."
        },
        {
          "claim": "Securities Act Sections 5(a) and 5(c) (Against BAM Trading for Unregistered Offers and Sales of Staking Program)",
          "ruling": "sustained",
          "reasoning": "Howey met: pooled crypto staked by BAM expertise/infrastructure, APYs, slashing coverage, low minimums vs. independent staking; common enterprise/profits from efforts. Unregistered public offers to U.S. users; no exemption. Facts (website promotions, terms, pool mechanics) sufficient."
        },
        {
          "claim": "Exchange Act Section 5 (Against Binance for Failing to Register as Exchange for Binance.com)",
          "ruling": "sustained",
          "reasoning": "§5 requires registration for 'exchanges' under §3(a)(1)/Rule 3b-16: brings together buyers/sellers via non-discretionary matching (MatchBox engine, order book). Binance.com matches/executes securities trades (e.g., BNB/Crypto Securities), U.S. nexus (solicitation, VIPs, volumes). No exemption; unregistered operation via interstate commerce. Detailed platform description survives."
        },
        {
          "claim": "Exchange Act Section 15(a) (Against Binance for Failing to Register as Broker-Dealer for Binance.com)",
          "ruling": "sustained",
          "reasoning": "§15(a) mandates broker-dealer registration for effecting securities transactions for others' accounts. Binance solicits U.S. users, handles orders/funds/securities, OTC as principal/dealer. No registration/exemption; strict liability with facts (APIs, custody, fees)."
        },
        {
          "claim": "Exchange Act Section 17A(b) (Against Binance for Failing to Register as Clearing Agency for Binance.com)",
          "ruling": "sustained",
          "reasoning": "§17A(b) requires registration for clearing functions: intermediary payments/deliveries, central depository (omnibus wallets, ledger debits/credits). Binance settles all trades/securities; no exemption. Adequate allegations."
        },
        {
          "claim": "Exchange Act Section 5 (Against Binance and BAM Trading for Failure to Register as Exchange for Binance.US)",
          "ruling": "sustained",
          "reasoning": "Group of persons (Binance tech + BAM) constitutes exchange: matching engine/order book for securities. Ongoing U.S. operations; unregistered. Facts (SLAs, control, trading) plead viable claim."
        },
        {
          "claim": "Exchange Act Section 15(a) (Against BAM Trading for Failing to Register as Broker for Binance.US)",
          "ruling": "sustained",
          "reasoning": "BAM effects transactions (solicits, onboards, handles fiat/crypto via Trust Co., OCBS/Convert/OTC). Broker functions clear; unregistered."
        },
        {
          "claim": "Exchange Act Section 17A(b) (Against Binance and BAM Trading for Failing to Register as Clearing Agency for Binance.US)",
          "ruling": "sustained",
          "reasoning": "Joint clearing/custody (Binance wallets/ledger until 2022+, settlements). §3(a)(23) met; unregistered."
        },
        {
          "claim": "Exchange Act Sections 5, 15(a), and 17A(b) (Against Zhao as Control Person over Binance for Binance.com)",
          "ruling": "sustained",
          "reasoning": "§20(a) control liability requires primary violation (pled) + control (ownership, CEO, directs ops/decisions, quotes). Culpa required but inferred from direction; detailed (chats, funding, vetoes)."
        },
        {
          "claim": "Exchange Act Sections 5, 15(a), and 17A(b) (Against Zhao as Control Person over Binance and BAM Trading for Binance.US)",
          "ruling": "sustained",
          "reasoning": "Same standard; Zhao's control pled extensively (81% ownership BAM Mgmt, board chair, directs hires/funding/assets/market makers, overrules CEOs via 'shackles'/Project 1776 docs)."
        },
        {
          "claim": "Securities Act Sections 17(a)(2) and (a)(3) (Against BAM Management and BAM Trading)",
          "ruling": "sustained",
          "reasoning": "No scienter needed for (2)/(3): material misreps/omissions (surveillance claims in rules/Pitch Deck/Manual despite no controls until 2022, inflated volumes sans disclosure of wash trading), deceptive acts (touting vendors/volumes). Obtained $200M equity + fees; materiality (volume/credibility key per Zhao); reliance not required in SEC context."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 50938,
      "completion_tokens": 1956,
      "total_tokens": 54160
    },
    "case_id": "dcd-1_23-cv-01599"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs, on behalf of a proposed class of all persons and entities (excluding Defendants) who purchased or acquired Danaher Corporation ('Danaher') securities between January 27, 2022, and October 23, 2023 (the 'Class Period'), and were damaged thereby, bring this securities fraud class action against Danaher (a Delaware conglomerate in biotechnology, life sciences, and diagnostics segments, trading as DHR on NYSE) and Individual Defendants: Rainer M. Blair (President and CEO), Matthew R. McGrew (CFO), and Emmanuel Ligner (VP and Group Executive of Biotechnology segment, former CEO of Cytiva). The alleged fraudulent conduct involves Defendants' materially false and misleading statements and omissions regarding the health, demand, and growth prospects of Danaher's bioprocessing business (primarily Cytiva and Pall, ~$7.5B revenue, ~25% of total sales), a key part of its Life Sciences/Biotechnology segment that boomed during COVID-19 but faced post-pandemic headwinds. Key factual allegations: (1) COVID-related demand waned as disease became endemic; (2) large pharma customers stockpiled inventory from pandemic-era orders (due to long lead times) and repurposed it, reducing new orders; (3) smaller biotech startups faced funding shortages amid rising rates, prioritizing projects and delaying/canceling; (4) non-COVID bioprocessing orders declined (e.g., 20% in Q3 2022, mid-teens Q4 2022, worse in 2023 including China); (5) Defendants issued/reaffirmed overly optimistic guidance multiple times (e.g., high single/low double-digit growth for bioprocessing 2022/2023, specific COVID sales forecasts like $2B 2022 reduced stepwise to $800M; $500M 2023 to $150M), dismissing risks like stockpiling/funding as transitory; (6) internal processes (monthly Forecasts via OneStream, DBS 'voice of customer') and close customer contact revealed truths early, but Defendants allegedly overrode subsidiary projections (per CW1-CW4 from communications/EAS); (7) piecemeal downward revisions (e.g., Oct 20, 2022; Jan 24, Apr 25, Jul 25, Oct 24, 2023) caused stock drops (e.g., ~6% Oct 2022, 5.2% Jan 2023, 9% Apr 2023); (8) insider sales (Blair ~$12.2M, McGrew ~$5.6M at peaks); (9) Ligner departed post-Class Period amid misses. Legal claims: Count I - Violations of §10(b)/Rule 10b-5 against all Defendants (misleading statements/omissions, including Item 303 failures in SEC filings); Count II - §20(a) control person liability against Blair/McGrew (premised on primary violation). Significant dates: Class Period start aligns with 4Q21 earnings introducing 'base business core revenue'; end pre-Oct 24, 2023 final revision; key revision dates as above with stock declines.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under Fed. R. Civ. P. 12(b)(6) and PSLRA, the complaint must plead: (1) material misrepresentation or omission; (2) scienter; (3) connection to purchase/sale of security; (4) reliance; (5) loss causation; and (6) economic loss (Dura Pharms. v. Broudo, 544 U.S. 336 (2005)). PSLRA requires particularity in alleging falsity (15 U.S.C. §78u-4(b)(1)) and strong inference of scienter (§78u-4(b)(2)). Here, complaint pleads specific statements (e.g., Blair's repeated assurances of high single/low double-digit bioprocessing growth, $2B/$1B/$500M COVID sales forecasts on 1/27/22, 4/21/22, 7/21/22, etc., denying stockpiling/funding risks despite analyst probes), alleged false when made as untethered to customer activity/forecasts (e.g., non-COVID orders already declining 20% Q3 2022 per 10/20/22 admission masked as 'cadence change'). Falsity/misleading nature supported by stepwise guidance cuts matching concealed risks (COVID decline, stockpiling ~75% large customers, funding crunch small biotechs), Item 303 omissions in filings (known trends materially impacting revenues), and CWs (e.g., CW4 overhearing Blair 'yelling' and 'mak[ing] up' Q2 2022 projections overriding subsidiaries; CW1 on corporate overrides). Materiality plausible as bioprocessing was core (~25% sales, 'crown jewel' post-$35B acquisitions), analysts/investors fixated (multiple calls). Scienter strongly inferred via: core operations doctrine (Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007)) for executives overseeing Life Sciences/Biotech; CWs on internal knowledge/pressure; SARs (Blair $12.2M/88% holdings, McGrew $5.6M/135%, timed post-statements pre-drops); Ligner's suspicious post-miss departure; repeated specific denials to analysts despite data (e.g., daily metrics, customer surveys). Reliance presumed via fraud-on-the-market (Basic Inc. v. Levinson, 485 U.S. 224 (1988)); efficient market pled (high volume, analyst coverage). Loss causation via corrective disclosures (materialization: stepwise revelations of concealed risks caused drops ~5-9% on volume, e.g., 10/20/22 first growth cut). No safe harbor (statements mix historical/present falsity with forward-looking; inadequate cautions; known falsity). Against Ligner: fewer statements (9/15/22), but attributable as group exec touting growth. Claim plausibly pled against all."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "Section 20(a) imposes liability on controlling persons who culpably participate in primary §10(b) violation (17 C.F.R. §78t(a); Parmalat Sec. Litig., 376 F. Supp. 2d 472 (S.D.N.Y. 2005)). Requires: (1) primary violation; (2) control (power to direct/influence primary violator); (3) culpable participation (knowing/reckless). Primary §10(b) survives (see above). Blair (CEO, ex-Life Sciences head) and McGrew (CFO, signed 8-Ks, oversaw rollups) plausibly controlling: signed/disseminated statements, final say on forecasts per CWs, direct involvement. Culpability via same scienter facts as §10(b) (core knowledge, SARs, overrides). Plausibly pled."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 36331,
      "completion_tokens": 1531,
      "total_tokens": 39006
    },
    "case_id": "dcd-1_23-cv-02055"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "The complaint is a securities class action alleging misconduct in connection with the August 31, 2023, take-private merger (the 'Merger') of Focus Financial Partners Inc. ('Focus' or the 'Company'), a wealth management firm in the RIA sector, by Clayton, Dubilier & Rice ('CD&R') at $53 per share. Lead Plaintiffs are institutional investors (AltShares Event-Driven ETF, AltShares Merger Arbitrage ETF, Kryger Event Fund Ltd., Kryger Enhanced Fund Ltd., and ODS Capital LLC) who held shares as of the June 9, 2023 record date, voted on the Merger, and exchanged shares in the Merger, claiming damages from receiving inadequate consideration. Defendants include Focus; Special Committee Defendants (directors LeMieux (Chairman), Neuhoff, Morganroth, Feliciani); Board Defendants (CEO/Chairman Adolf, COO/Board member Kodialam, Stone Point designees Carey and Muhtadie); Officer Defendants (CFO Shanahan, Head of M&A Chang, General Counsel McGranahan); Stone Point Capital LLC (20.6% owner with board seats and influence via nominating/compensation agreements and credit facility); financial advisors Goldman Sachs and Jefferies; CD&R; and law firms V&E and Potter Anderson. The Class Period for §§10(b)/20(a) claims is February 27, 2023 (Merger announcement) to August 31, 2023 (Merger close) for sellers damaged thereby; for §§14(a)/20(a), record date holders entitled to vote. Key dates: Sale process initiated summer 2022 amid 'challenging market'; Special Committee formed November 1, 2022; CD&R exclusivity January 30, 2023 (extended); Merger announced February 27, 2023; preliminary proxy April 25, 2023; definitive proxy June 12, 2023; Supplemental Proxy July 6, 2023 (revealing some conflicts); vote July 14, 2023; close August 31, 2023. Alleged fraudulent conduct: Defendants ran a conflicted, deficient sale process favoring financial buyer CD&R (offering $53/share with equity rollover/job retention for management/Stone Point) over strategic buyers, stiff-arming superior $55/share bidder 'Party I' (redacted RIA firm whose CEO met Adolf September/November 2022 but was delayed/deterred, denied diligence/exclusivity granted to CD&R). Conflicts: Stone Point sought $90M+ TRA lump-sum windfall, equity rollover/new investment (disincentivized higher bids); management preferred financial buyer for job/equity security; Special Committee received $729k-$944k unique payments (TRAs, accelerated equity, 3.5x-6x fee hikes self-approved pre-Merger vote), undisclosed personal/business ties to Adolf/Stone Point/CD&R; Goldman conflicted via Stone Point/CD&R ties, parallel NKSFB/KSFB sale limiting Focus bidder pool (7 bidders contacted only post-signing); Jefferies 8x discretionary fee hike ($1M to $8M) pre-fairness opinion. Process flaws: Limited to financial buyers despite RIA synergies; no timely strategic outreach; CD&R informational edge (months of diligence pre-Party I bid); no TRA waivers despite $1.42-$1.85/share boost potential; go-shop ineffective. Misrepresentations/omissions in February 27 press release, proxy, Supplemental Proxy: Falsely touted 'robust,' 'fair' process yielding 'best value'; 'independent/disinterested' Special Committee; omitted conflicts, Party I stiff-arming/prior interest, bidder deterrence, CD&R management rollover incentives, Goldman/Jefferies conflicts/fee hikes, Stone Point non-agnosticism. Claims: (1) §10(b)/Rule 10b-5 against all Defendants (scheme/misstatements depressing share price); (2) §14(a)/Rule 14a-9 against Focus/Special Committee/Board/Officer Defendants (misleading proxy); (3) §20(a) control liability against Special Committee/Board/Officer Defendants.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5(a)-(c)",
          "ruling": "dismissed",
          "reasoning": "To state a claim under §10(b) and Rule 10b-5, Plaintiffs must plead: (1) material misrepresentation or omission, (2) scienter, (3) connection with purchase/sale of security, (4) reliance, (5) economic loss, and (6) loss causation (Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005); Halliburton Co. v. Erica P. John Fund, Inc., 573 U.S. 258 (2014)). PSLRA requires particularity (15 U.S.C. §78u-4(b)) and strong scienter inference (Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007)). While complaint details alleged omissions/misstatements in press release/proxy (e.g., process robustness, Special Committee independence), primarily tied to proxy vote, not trading, and pleads scienter via detailed conflicts/core operations inference/confidential docs, it fails loss causation. Class are post-announcement sellers (including merger exchangers) claiming artificial deflation below 'true value' from superior bidder suppression. No corrective disclosure revealed truth causing price drop; post-announcement price reflected/held near announced $53 deal price (chart shows tethering, not inflation then deflation). No out-of-pocket loss beyond deal price; merger closed as announced. Deal-submergence theory insufficient without disclosure/event linking misreps to loss (Janus Merger Partners, LLC v. OFI Risk Arbitrage, LLC, No. 18-913, 2025 WL 4564788 (D. Del. Sept. 24, 2025) (dismissing similar); In re Xcelera.com Sec. Litig., 430 F.3d 503 (1st Cir. 2005)). Fraud-on-market reliance presumed but causation absent. Dismissed without prejudice."
        },
        {
          "claim": "Section 14(a) of the Exchange Act and Rule 14a-9",
          "ruling": "sustained",
          "reasoning": "§14(a)/Rule 14a-9 prohibits materially misleading proxy solicitations for shareholder vote (TSC Indus., Inc. v. Northway, Inc., 426 U.S. 438 (1976): omission material if reasonable shareholder would view as significantly altering total mix). No scienter/relief/reliance required; negligence suffices (Mills v. Elec. Auto-Lite Co., 552 U.S. 438? No, 396 U.S. 375 (1970)). Complaint pleads with particularity numerous omissions/misstatements in proxy (filed June 12, 2023; Supp. July 6) re Merger vote: (1) Special Committee conflicts (undisclosed $729k-$944k payments, self-approved fee hikes timed pre-approval, personal ties to Adolf/Stone Point/CD&R); (2) process flaws (Party I CEO contacts Sept/Nov 2022 omitted, stiff-arming despite superior $55 bid, strategic exclusion, bidder deterrence by favoritism, no level playing field); (3) Stone Point/management incentives (TRA windfalls, rollover/job retention by CD&R omitted from offer descriptions); (4) advisor conflicts (Goldman NKSFB parallel sale limiting bidders, undisclosed ties/fees; Jefferies 8x fee hike pre-opinion); (5) false touts of 'robust/fair' process, 'best value,' independence. Proxy central to uninformed vote approving inadequate $53 consideration (Supp. Proxy too little/too late). Reasonable shareholder would view as altering mix on fairness (e.g., Corwin cleansing inapplicable if materially misleading proxy). Detailed from confidential docs (FOCAP) satisfies PSLRA. Transaction causation presumed (approval essential link). Sustained."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "dismissed_in_part",
          "reasoning": "§20(a) imposes control person liability for primary §10(b)/14(a) violation if 'culpable participation' (controlling influence + direct/indirect participation causing violation) (Belmont v. MB Inv. Partners, Inc., 708 F.3d 470 (3d Cir. 2013)). Dismissed as to §10(b)/10b-5 (no primary violation). Sustained as to §14(a)/14a-9: Individual Defendants (Special Committee/Board/Officers) signed proxy/oversaw process ('By Order of Board'; Adolf/McGranahan signatures); signed resolutions (e.g., fee hikes); attended meetings; possessed control via positions; culpable via review/approval of disclosures despite knowledge of facts from docs/minutes. Direct involvement in conflicted process/disclosures. Scienter not required for 14(a) control. Sustained re 14(a); dismissed re 10(b). Without prejudice re 10(b)."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 33624,
      "completion_tokens": 1941,
      "total_tokens": 37096
    },
    "case_id": "dde_ 23_cv_1466"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs Kim Kengle (as trustee) and Roseanne Lacy, on behalf of a class of Walmart Inc. shareholders who purchased common stock between March 31, 2017 (filing of Walmart's 2016 10-K), and December 22, 2020 (DOJ civil complaint filing), and held shares on March 24, 2020, and/or December 22, 2020, allege securities fraud against Defendants Walmart Inc., CEO Douglas C. McMillon, and CFO M. Brett Biggs. The complaint claims Walmart systematically violated the Controlled Substances Act (CSA) as a pharmacy (filling invalid opioid prescriptions despite red flags) and distributor (failing to monitor/report suspicious orders), breaching a 2011 nationwide DEA settlement (MOA) requiring compliance measures. Key facts include: internal documents (e.g., 2013 CSRA, 2014 PSW warning board of 'severe' financial/reputational harm from non-compliance, 2015 proposal for SOM enhancements); DEA raid (Dec. 2016) triggering EDTX DOJ Criminal Investigation (2016-2018, near-indictment March-May 2018 averted via lobbying/hiring ex-DOJ Rachel Brand); parallel Civil Investigation (from Nov. 2017, expanded via Working Group/omnibus subpoena); >50 DEA admonition letters; pharmacist complaints ignored for sales pressure/incentives; Opioid MDL findings (liability, injunction). Defendants allegedly concealed these via false SEC filings (10-Ks/10-Qs claiming all 'reasonably possible' material liabilities disclosed, violating Item 103/ASC 450; boilerplate pharmacy risks omitting actual investigations/CSA breaches); false 'opioid stewardship' PR; SOX certifications. Corrective disclosures: ProPublica article (Mar. 25, 2020, revealing investigations/MOA, ~5% stock drop); DOJ complaint (Dec. 22, 2020, alleging massive CSA violations, ~1.9% drop). Claims: Count I (§10(b)/Rule 10b-5 against all); Count II (§20(a) against Individuals).",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under §10(b)/Rule 10b-5, the complaint must plausibly allege: (1) material misrepresentation/omission, (2) scienter, (3) connection with purchase/sale, (4) reliance (Basic fraud-on-the-market presumption), (5) economic loss, and (6) loss causation (Dura Pharmaceuticals). Iqbal/Twombly plausibility satisfied. Material omissions: Walmart's SEC filings affirmatively stated all 'reasonably possible' material liabilities disclosed (violating Item 103 for contemplated govt proceedings like EDTX indictment/Civil Investigation; ASC 450 for 'reasonably possible' loss contingencies from CSA breaches/2011 MOA violations, known via PSW/CSRA); boilerplate pharmacy risks omitted actual materialized risks (investigations); false 'stewardship' PR omitted contrary conduct. Publicly sourced (ProPublica, DOJ complaint, MDL docs/exhibits) but detailed allegations (e.g., specific timelines, internal emails, PSW to board) render omissions actionable half-truths, creating duty to speak. Scienter: Strong inference via core operations doctrine (pharmacy ~10% sales, opioids drove traffic); Individual Defendants' positions (McMillon: Ethics Committee, approved DOJ presentation, opioid discussions; Biggs: CFO/Ethics Committee); core docs (2014 PSW: 'severe' harm 'likely,' board-informed; compliance memos prioritizing sales); hiring Brand amid investigation; concealment efforts (withheld docs from prosecutors/MDL); motive (sales/profits). Collective allegations compel inference of intent/recklessness over nonculpable explanations. Reliance/loss causation: FOTM applies (NYSE-traded, analyst coverage, efficient market, rapid reaction to news); specific drops (~5% Mar. 25, 2020; ~1.9% Dec. 22-23, 2020) post partial disclosures tie to concealed risks. Motion denied; claim survives."
        },
        {
          "claim": "Section 20(a)",
          "ruling": "sustained",
          "reasoning": "§20(a) control person liability requires: (1) primary §10(b) violation by controlled entity; (2) culpable participation (knowing assistance in primary violation with intent to deceive/malice/recklessness, or 'use of power to commit wrongdoing'). Primary §10(b) survives, satisfying first element. Culpable participation: Individuals 'controlled' Walmart (signed all Class Period 10-Ks/10-Qs/SOX certs attesting accuracy/disclosure controls; Ethics Committee oversight of compliance risks); knew/approved omissions (McMillon: direct DOJ involvement/personal knowledge per MDL; Biggs: CFO responsibility for contingencies/filings); reckless in certifying false filings despite access to contrary facts (PSW, compliance reports). Allegations of signing misleading reports amid known risks suffice for 'culpable participation' at pleading stage (e.g., In re Alphabet). No need for 'special rule' dismissal; holistic scienter inference from §10(b) extends. Motion denied; claim survives."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 44307,
      "completion_tokens": 1120,
      "total_tokens": 46244
    },
    "case_id": "dde_21_cv_55"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs are twenty individual investors (Kristoffer Jon Hind, Jason Thomas Waiton, Christopher Campbell, Paul Douglas Stoeppelwerth, Lucas Longmire, Thomas Blair Phillips, Tyler Jenkins, Jorden David Neil Malcolm, Robert Taylor Yates, Rafael Reyes Salmeron, Ryan Anthony Floyd, Matt Scott Vogel, Mark Alan Bentley, Peter Shane Donahue, Agata Agnieszka Powers, Avya Lindsey Waiton, Timothy Michael Morgan, Tarsis Carvalho Humphreys, Zachary Michael Sellers, and Brandon Michael Harrold) residing primarily in the United States (with one in Canada), who collectively invested over $27 million in forex trading accounts. Defendants are CFT Solutions, LLC (Delaware LLC operating from Miami, FL), FxWinning Limited (Hong Kong company with operations in Cyprus, Dubai, and Miami), and individual defendants Renan de Rocha Gomes Bastos (CFT founder/CEO), Arthur Percy (CFT COO), Rafael Brito Cutie (FxWinning co-owner/CEO), Roman Cardenas (FxWinning VP), and David Merino (FxWinning founder/owner). The alleged misconduct is a fraudulent Ponzi-like scheme where defendants promoted a purported high-frequency trading (HFT) platform and algorithm invented by Merino, promising high returns (e.g., 410% yearly, 71% success rate), fund security via segregated accounts, Client Money Insurance, regulation, and unrestricted withdrawals per terms of service. Plaintiffs were solicited via CFT's Telegram channel (started July 2021), FxWinning websites, de Rocha's Zoom sessions, in-person events (Miami Mastermind Jan. 2022, yacht party Jan. 2022, Bahamas summit Dec. 2022), and joint marketing. Plaintiffs opened FxWinning accounts (accessed via CFT), signed limited POAs granting CFT 40-50% management fees for trading, and deposited funds from approx. Feb. 2021 to Feb. 2023. Initial withdrawals (through Dec. 2022) lulled trust; from Jan. 2023, defendants blocked all citing new KYC/AML from liquidity provider, despite May/June 2023 emails confirming completion and 15-day processing promises. FxWinning announced service cessation June 22, 2023, but no funds released. Key facts: fake KPMG audit, fabricated dashboards/profits, no actual trades/software, defendants' self-withdrawals/commissions (e.g., Percy $141k), personal asset purchases (e.g., de Rocha/Merino properties), prior schemes by de Rocha; press/investigations label pyramid. Total withheld: $27.3M. Some plaintiffs (Hind, Waiton, Stoeppelwerth, Jenkins, Malcolm, Salmeron, Floyd, Vogel, Bentley, Donahue, Powers, Waiton, Morgan, Tarsis, Sellers, Harrold) agreed to arbitrate Counts I, II, III, IV, VI-VII, VIII-XI vs. CFT, de Rocha, Percy. No explicit class period, but relevant dates span account openings Feb. 2021-Feb. 2023, withdrawal blocks Jan. 2023, false assurances May-June 2023, cessation June 2023. Legal claims: Count I (Secs. Act §§5/12(a)(1) vs. CFT/FxWinning); II (Exch. Act §10(b)/Rule 10b-5 vs. CFT/FxWinning/de Rocha/Cardenas/Brito); III (CEA §§6b/6e/6o/25 vs. CFT/FxWinning/de Rocha/Cardenas/Brito); IV (Fla. Sec. §§517.301/517.211 vs. CFT/FxWinning/de Rocha/Cardenas/Brito); V (Breach Contract vs. FxWinning); VI (Breach Fiduciary Duty vs. all); VII (Fraud Inducement vs. CFT/FxWinning/de Rocha/Cardenas/Brito); VIII (Negligent Misrep vs. CFT/FxWinning/de Rocha/Cardenas/Brito); IX (Conversion vs. all); X (Unjust Enrichment vs. all); XI (Civil Conspiracy vs. all).",
      "claim_rulings": [
        {
          "claim": "Sections 5 and 12(a)(1) of the Securities Act of 1933, 15 U.S.C. §§ 77e and 77l(a)(1)",
          "ruling": "sustained",
          "reasoning": "To state a claim under §§5(a)/(c) and 12(a)(1), plaintiffs must plausibly allege (1) the accounts are 'securities,' (2) use of interstate commerce to offer/sell unregistered securities. Under Howey, the accounts qualify as investment contracts: (1) investment of money ($27M+ deposits); (2) common enterprise (pooled funds managed via joint CFT/FxWinning HFT platform, fortunes tied to defendants' software/efforts, joint events/marketing); (3) profits solely from others' efforts (plaintiffs passive, no trading control, reliant on defendants' algorithm). Sales via websites, Telegram, U.S. events used interstate commerce. No registration alleged/filed. Strict liability applies; factual allegations (solicitations, POAs, terms) satisfy Iqbal/Twombly. Subject to arbitration for some plaintiffs vs. CFT, but claim survives vs. FxWinning and non-arbitrating plaintiffs."
        },
        {
          "claim": "Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "PSLRA requires particularized facts showing (1) material misrepresentation/omission; (2) scienter; (3) connection to security purchase; (4) reliance; (5) economic loss; (6) loss causation. Misreps detailed/specific: false promises of withdrawable funds (terms §3.4, repeated assurances), high returns (Telegram screenshots 410%/44%/71%, dashboards), security/regulation/CMI/KPMG audit (fake per belief), made via websites/Telegram/Zoom/events pre/post-investment. Material: induced $27M deposits. Scienter: strong inference via core operations inference (defendants controlled platform/knew no trades/fake docs), motive (fees/commissions, self-withdrawals/property buys), pattern (prior schemes). Reliance/transactional nexus: but-for misreps, per complaint. Loss: $27M withheld; causation: losses materialized post-withdrawal blocks/revelations. Falsity particularized ('upon info/belief' with basis: no withdrawals despite promises, press/investigations). Survives vs. named defendants."
        },
        {
          "claim": "Commodity Exchange Act, Sections 6b, 6e, 6o, and 25, 7 U.S.C. §§ 6b, 6e, 6o, and 25",
          "ruling": "dismissed_in_part",
          "reasoning": "CEA §25(a) private right requires fraud by unregistered CTA/CPO/AP in commodity interests (forex qualifies as commodity). Pleaded in alternative 'to extent not security,' but Howey analysis supra renders accounts securities under SEC jurisdiction, preempting CEA for pooled managed forex (CFTC/SEC MoU). §§6b(a)/6o(1): fraud in solicitation plausible (misreps as in Count II). §6e: unregistered floor trading. But duplicative of securities claims; dismissed as to CFT/FxWinning/de Rocha/Cardenas/Brito where securities viable, sustained only if discovery shows spot forex not security (unlikely). Arbitration impacts some plaintiffs."
        },
        {
          "claim": "Florida Securities and Investor Protection Act, Sections 517.301 and 517.211",
          "ruling": "sustained",
          "reasoning": "§517.301 prohibits fraud in security sale (securities mirror federal Howey); §517.211 liability for violators/officers/agents. Allegations track §10b-5: schemes (Ponzi), untrue statements/omissions (returns/security), fraudulent practices. Particularity under Fla. R. Civ. P. 1.120(b) (mirrors FRCP 9b) met via specifics (statements, dates, screenshots). Joint/several liability for sellers/participants (all named). No scienter for some subsections. Sustained."
        },
        {
          "claim": "Breach of Contract",
          "ruling": "sustained",
          "reasoning": "Elements: valid contract, material breach, damages, causation. FxWinning terms §3.4 explicit 'right to withdraw... at all times upon request'; plaintiffs performed (deposits); breach (no withdrawals despite requests/assurances); damages ($27M). Enforceable click-wrap terms. Plausibly states claim."
        },
        {
          "claim": "Breach of Fiduciary Duty",
          "ruling": "dismissed",
          "reasoning": "Elements: fiduciary relationship, breach, damages. Limited POA authorizes trading only, disclaims broader duties; no general agency/principal or trust relationship beyond contract (arms-length investment). No plausible special relationship of trust/confidence (passive investors in managed accounts). Fails Twombly; ordinary negligence/contract suffices elsewhere."
        },
        {
          "claim": "Fraud in the Inducement",
          "ruling": "sustained",
          "reasoning": "FRCP 9b particularity met: who (named defendants/execs), what (specific false reps: withdrawable funds, returns, security/regulation/audit), when (Telegram dates, events 2021-2023, emails May/June 2023), where (online/U.S. events), how (to induce deposits), scienter (knowledge false), reliance, damages. Distinct from contract; extrinsic fraud."
        },
        {
          "claim": "Negligent Misrepresentations",
          "ruling": "dismissed",
          "reasoning": "Florida requires (1) false info; (2) negligent supply in business transaction; (3) for guidance; (4) justifiable reliance. No plausible special duty beyond contract (no privity/intimate nexus for pecuniary loss; see Soriano v. Wheaton). Duplicative of fraud/contract; fails as negligence per se not alleged."
        },
        {
          "claim": "Conversion",
          "ruling": "sustained",
          "reasoning": "Florida: wrongful exercise of dominion over plaintiff's property inconsistent with ownership. Funds identifiable (specific account #'s/balances totaling $27M); defendants wrongfully withheld/refused return post-demand, exercised control (self-withdrawals). Money convertible if segregated/identifiable (S & R Co. v. Air Control). Plausible."
        },
        {
          "claim": "Unjust Enrichment",
          "ruling": "dismissed_in_part",
          "reasoning": "Elements: benefit conferred, retention unjust. Valid where no adequate contract remedy (quantum meruit). Dismissed vs. FxWinning (express contract Count V); sustained vs. others (no direct contract, benefits via fees/commissions/siphoned funds). Inequitable retention alleged."
        },
        {
          "claim": "Civil Conspiracy",
          "ruling": "sustained",
          "reasoning": "Florida: agreement to engage in tortious act, overt act in furtherance, injury. Underlying torts (fraud, conversion viable); plausible agreement (joint entities/marketing/events, coordinated blocks/lies despite fake KYC). Particularized roles (e.g., Merino software, de Rocha sales, Brito KYC). Joint liability."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 15610,
      "completion_tokens": 2451,
      "total_tokens": 20814
    },
    "case_id": "flsd-1_23-cv-23139"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Lead Plaintiffs Sudhakara R. Murikinati, Jerry Nixon, Benjamin Sandmann, and Jeff S. Turnipseed bring this securities class action on behalf of all purchasers of GoHealth, Inc. ('GoHealth') Class A common stock pursuant and/or traceable to the Registration Statement issued in connection with GoHealth's IPO on July 17, 2020 (the 'Class Period,' limited to IPO purchases). Defendants include: (1) GoHealth, a Delaware corporation operating a health insurance marketplace focused on Medicare Advantage plans; (2) Individual Defendants Clinton P. Jones (CEO and Co-Chair), Brandon M. Cruz (Chief Strategy Officer and Co-Chair), and Travis J. Matthiesen (CFO), who signed the Registration Statement ('Section 11 Defendants' together with underwriters); (3) NVX Holdings, Inc. (controlled by Founders Jones and Cruz) and Centerbridge Partners entities (private equity sponsor owning controlling interest post-IPO) ('Section 15 Defendants' together with GoHealth and Individual Defendants); and (4) Underwriter Defendants Goldman Sachs & Co. LLC, BofA Securities, Inc., and Morgan Stanley & Co. LLC, who underwrote the IPO of 44.5 million shares at $21.00 per share, raising over $900 million. The alleged misconduct involves material misstatements and omissions in the Registration Statement, which touted GoHealth's rapid growth (e.g., 104.1% revenue increase in 1Q2020, industry-leading LTV/CAC ratio of 3.9x in 2019), scalability, strong carrier relationships (especially with Humana and Anthem, comprising 74% of 1Q2020 revenues), and focus on Medicare segments without disclosing: (1) unsustainable reliance on two carriers had maximized growth, necessitating a radical shift to rapid expansion with new carriers (e.g., UnitedHealth, Aetna) and SNPs, planned as a 2020 'investment year'; (2) this shift would cause near-term drags on LTV/CAC via lower commissions, higher marketing costs, reduced persistency/increased churn, less data for LTV estimates, and shift to non-commissionable revenue; and (3) violations of SEC Items 303, 105, and SAB 104 by omitting known trends/uncertainties. Key supporting facts: Pre-IPO concentration (85% Medicare revenues from Humana/Anthem); post-IPO revelations (Aug. 19, 2020 earnings call admitting new carrier ramp-up with lower LTVs/churn; Dec. 2, 2020 conference confirming 2020 investment year with LTV compression); stock decline from $21 to $10.05 (52% drop); underwriters' alleged due diligence failure. Claims: (1) Section 11 (strict liability for untrue statements/omissions in Registration Statement); (2) Section 15 (control person liability). Significant dates: IPO priced July 14, 2020, closed July 17, 2020; 2Q2020 results Aug. 19, 2020; 3Q2020 Nov. 11, 2020; Evercore conference Dec. 2, 2020.",
      "claim_rulings": [
        {
          "claim": "Section 11 of the Securities Act (15 U.S.C. § 77k)",
          "ruling": "sustained",
          "reasoning": "Section 11 imposes strict liability on issuers, signers, and underwriters for material misstatements or omissions in a registration statement, requiring only that plaintiff purchased traceable securities and sustained damages; no scienter, reliance, or loss causation pleading needed (unlike Exchange Act claims). Plaintiffs adequately allege material misrepresentations/omissions with particularity, identifying specific Registration Statement statements (e.g., scalability improves LTV/CAC; carrier expansion enhances efficiency/relationships; rapid growth from Medicare focus) that were misleading absent disclosure of known trends: unsustainable two-carrier concentration (74% revenues), planned 2020 'investment year' expansion causing LTV drags (lower commissions, higher CAC, churn), and Item 303/SAB 104 violations for omitting known unfavorable trends reasonably likely to materially impact revenues (e.g., post-IPO admissions confirm pre-IPO knowledge via real-time data). Risk factors were boilerplate/generic, not bespeaking caution adequately (e.g., omitted specific carrier expansion risks already materializing). Issuer GoHealth strictly liable as registrant. Individual Defendants (signers) plausibly failed reasonable investigation duty given executive roles and access to real-time metrics. Underwriters plausibly negligent in due diligence, as complaint alleges participation in roadshow/drafting without verifying omissions (negative inferential defense unavailable at pleading stage per In re Morgan Stanley Info. Fund Sec. Litig., 592 F.3d 347 (2d Cir. 2010)). Post-IPO disclosures and 52% stock drop support economic loss. Motion denied; claim survives."
        },
        {
          "claim": "Section 15 of the Securities Act (15 U.S.C. § 77o)",
          "ruling": "sustained",
          "reasoning": "Section 15 provides control person liability for Section 11 primary violations, requiring: (1) primary violation; and (2) control (power to direct management/policies plus culpable participation not required post-Janus Capital Grp., Inc. v. First Derivative Traders, 564 U.S. 135 (2011); In re First Interstate Bancorp Sec. Litig., 184 F.3d 1199 (10th Cir. 1999)). Section 11 sustained above establishes primary violation. Complaint plausibly alleges control: Individual Defendants as senior executives/directors with signing/due diligence duties; GoHealth as issuer controlling subsidiaries/employees; NVX Holdings/Centerbridge as controlling shareholders (post-IPO ~71% voting power, 'controlled company' per Nasdaq, influence over board/decisions per Registration Statement admissions). Registration Statement confirms Founders/Centerbridge 'exercise significant influence' over business/affairs. No heightened PSLRA scienter pleading; allegations of actual control suffice at motion stage (e.g., ownership, board seats, policy influence). Motion denied; claim survives."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 25274,
      "completion_tokens": 1288,
      "total_tokens": 27398
    },
    "case_id": "ilnd-1_20_cv_05593"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiff DarkPulse, Inc., a Delaware corporation with its principal place of business in New York City and stock traded on the OTC markets, brings this action against Defendants FirstFire Global Opportunity Fund, LLC (a Delaware LLC with principal place of business in New York City) and Eli Fireman (FirstFire's managing member and a New York resident). DarkPulse alleges that FirstFire operates as a 'toxic lender' or unregistered securities dealer, making predatory convertible promissory note loans to microcap companies like DarkPulse, converting the debt into massively discounted shares (totaling over $38 million in market value from $975,000 in loans), and immediately selling the shares into the public market, depressing DarkPulse's stock price and diluting shareholders. Key factual allegations include: (1) September 2018 Note (face $247,500 from $225,000 cash, 8% interest, 30% discount to 20-day low price), with 18 conversions from June 2019 to February 2021 yielding 879.4 million shares worth ~$10.7 million; (2) April 2021 Note (face $825,000 from $750,000 cash, 10% interest, fixed $0.015/share dropping to $0.005 on default, plus 60 million commitment shares worth ~$1.14 million), with full conversion on November 15, 2021, yielding 177.4 million shares worth ~$23.7 million; FirstFire's history of 200+ similar deals with 89+ microcaps since 2015 issuing over 1 billion shares; immediate post-conversion volume spikes indicating dumping; effective APRs of 61% (2018 Note) and 291% (2021 Note) exceeding NY's 25% criminal usury cap (including OID, discounts, commitment shares per Adar Bays); use of interstate commerce (website, wires, email); no SEC registration despite dealer activity; Fireman's control. No class is certified; this is a direct action by the issuer. Significant dates: Notes executed April 20, 2018 (September Note, purchased September 20, 2018), April 26, 2021 (April Note); conversions June 7, 2019–February 18, 2021 (September Note), November 15, 2021 (April Note); Adar Bays decision October 14, 2021. Legal claims: (1) §29(b) Exchange Act rescission for contracts made violating §15(a) (unregistered dealer); (2) §29(b) for performance violating §15(a); (3) §20(a) control liability against Fireman; (4) RICO §1962(c) for conducting enterprise affairs via unlawful debt collection (usury); (5) unjust enrichment; (6) constructive trust. Seeks rescission, return of shares minus principal, damages (treble under RICO), declaratory relief.",
      "claim_rulings": [
        {
          "claim": "Section 29(b) of the Exchange Act for contracts made in violation of Section 15(a) (Count I)",
          "ruling": "sustained",
          "reasoning": "To state a claim under §29(b), plaintiff must plausibly allege: (1) a contract; (2) made in violation of the Exchange Act or regulations; (3) plaintiff in contractual privity and within protected class; (4) violation integral, not collateral. Iqbal/Twombly plausibility standard applies. Here, detailed allegations plausibly show FirstFire is a 'dealer' under §3(a)(5)(A)–(B) (regular business of buying/selling securities for own account through interstate commerce, not mere trader/investor with bona fide intent), not exempt: 200+ similar convertible note purchases/conversions/sales since 2015 (EDGAR data, examples like DigitalTown), immediate dumping (volume spikes), no investment holding, predatory discounts (30-50%), profits on spread/markup; unregistered per §15(a)(1); Notes are securities (§3(a)(10)); transactions effected via wires/email/website. Plaintiff (issuer) protected class; violation (unregistered dealer activity) integral to formation/purchase. See SEC v. Almagarby, Big Apple Consulting (cited); Edgepoint Capital, Auctus Fund (private rescission). Survives dismissal."
        },
        {
          "claim": "Section 29(b) of the Exchange Act for performance of contracts violating Section 15(a) (Count II)",
          "ruling": "sustained",
          "reasoning": "Similar to Count I, but for performance/continuance involving violation. Complaint alleges FirstFire's conversions (debt-for-shares securities exchanges) and sales (177M+ shares dumped) were dealer transactions in interstate commerce, part of regular business, unregistered. Specific 18 conversions listed (September Note), full November 2021 conversion (April Note), post-conversion sales inferred from volumes/profits. Tacking under Rule 144 exploited despite underwriter-like distribution. Violation integral to performance (conversions core to Notes). Plausibly states claim; motion denied."
        },
        {
          "claim": "Section 20(a) of the Exchange Act – Control Person Liability against Fireman (Count III)",
          "ruling": "sustained",
          "reasoning": "§20(a) requires: (1) primary violation of Act; (2) defendant 'controlled' violator (power to direct culpable acts); (3) culpable participation (not good faith). Primary violations (Counts I-II) plausibly alleged. Fireman plausibly culpable controller: managing member of FirstFire Capital Management (FirstFire's manager); directed/approved deals, personally negotiated/signed both Notes/SPAs, controlled conversions/sales; 'ultimate decision-making.' Direct/indirect inducement, no good faith. See §15 for Exchange Act control standards. Survives."
        },
        {
          "claim": "RICO §1962(c) – Conducting Affairs of Enterprise Through Collection of Unlawful Debt (Count IV)",
          "ruling": "sustained",
          "reasoning": "Civil RICO §1964(c) requires: (1) §1962 violation causing (2) business/property injury. §1962(c): person employed/associated with enterprise conducts affairs through racketeering activity. Racketeering includes 'collection of unlawful debt' (§1961(1), (6): debt unenforceable >2x NY legal rate (25% criminally usurious, Penal Law §190.40), from usury lending business). Enterprise: 'FirstFire Lending Enterprise.' Fireman culpable person. Plausibly alleged: NY-governed Notes (amendment null per Adar Bays void ab initio); effective APRs 61%/291.52% (stated interest +10% OID + discounts + commitment shares as interest, per Adar Bays); business of usury (200+ loans); multiple collections (18+ conversions, full April Note); injury (dilution, $38M shares, price crash, financing harm). Multiple acts satisfy. No heightened Sedima/Hybrid pleading needed for unlawful debt. See RICO cases recognizing usury predicates. Survives."
        },
        {
          "claim": "Unjust Enrichment (Count V)",
          "ruling": "dismissed",
          "reasoning": "Unjust enrichment is quasi-contractual, available only absent express contract governing parties/relations. Here, claims arise from/duplicate express Notes/SPAs (seeking rescission thereunder); same conduct (shares/profits from conversions). Cannot plead in parallel to void contract claims. NY law (choice-of-law). Dismissed without prejudice; may recast as remedy."
        },
        {
          "claim": "Constructive Trust (Count VI)",
          "ruling": "dismissed",
          "reasoning": "Constructive trust is equitable remedy, not independent cause of action; requires wrongful acquisition/detention of identifiable property, no adequate legal remedy. Duplicative of rescission/unjust enrichment/equitable relief under §29(b)/RICO; legal damages available. Property (shares) identifiable but remedy follows other claims. Dismissed as standalone count; preserved as relief."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 10892,
      "completion_tokens": 1714,
      "total_tokens": 15264
    },
    "case_id": "nysd_1_21-cv-11222"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "This is a securities class action complaint alleging violations of federal securities laws arising from Defendants' false and misleading statements regarding Wells Fargo & Co.'s ('Wells Fargo' or 'the Bank') compliance with remedial consent orders issued in 2018 by the Federal Reserve Board ('FRB'), Office of the Comptroller of the Currency ('OCC'), and Consumer Financial Protection Bureau ('CFPB') (collectively, '2018 Consent Orders' or 'Regulators'). The 2018 Consent Orders imposed asset caps and required the Bank to submit and implement multi-stage plans to overhaul its governance, risk management, and compliance programs following prior scandals involving unauthorized accounts and other abuses. Lead Plaintiffs are institutional investors: Handelsbanken Fonder AB, Public Employees’ Retirement System of Mississippi, State of Rhode Island Office of the General Treasurer (on behalf of Employees’ Retirement System of Rhode Island), and Louisiana Sheriffs’ Pension & Relief Fund. They purchased Wells Fargo common stock during the Class Period (February 2, 2018 to March 12, 2020, inclusive) and suffered damages. Defendants are Wells Fargo and the 'Insider Defendants': Timothy J. Sloan (former CEO and Director), John R. Shrewsberry (former CFO), Charles W. Scharf (CEO from October 2019), C. Allen Parker (former General Counsel and interim CEO), and Elizabeth 'Betsy' Duke (former Board Chair and Risk Committee member). Key factual allegations include: (1) Regulators repeatedly rejected Wells Fargo's Stage 1 plans as 'materially incomplete,' 'poor-quality,' 'a plan for a plan,' lacking substance, with 'pervasive inaccuracies' and 'illogical timeframes' (specific rejection letters dated May 7, 2018 (FRB), July 24, 2018 (OCC), November 21, 2018 (OCC), March 11, 2019 (FRB)); (2) Internal admissions (e.g., Board emails calling submissions 'totally biffed it,' 'not going far enough,' 'deficient'); (3) Defendants' public statements falsely claiming plans were 'in place,' 'approved,' 'executing/implementing' them, and asset cap lift imminent (e.g., Sloan's 'fast track,' 'executing the plan'; Shrewsberry's 'last mile'; Parker's 'way down the road'; Duke's 'pretty well along'); (4) Concealment efforts (e.g., Sloan/Duke toning down proxy disclosures); (5) Congressional House Financial Services Committee reports (March 2020) deeming statements 'inaccurate/misleading'; (6) Resignations (Sloan March 2019, Duke/Quigley March 2020), $15M Sloan clawback; (7) Stock drops totaling $54B market cap loss after partial disclosures (e.g., Jan. 15, 2019 (-2.4%), Apr. 12, 2019 (-2.62%), Jan. 14, 2020 (-5.4%), March 2020 hearings (-22.5%)). Claims: Count I - §10(b)/Rule 10b-5 against Wells Fargo, Sloan, Parker, Duke, Shrewsberry; Count II - §20(a) control person liability against Insider Defendants (Sloan, Shrewsberry, Scharf, Parker, Duke). Significant dates: 2018 Consent Orders (Feb. 2 FRB, Apr. 20 OCC/CFPB); first rejections (May/July 2018); Sloan's congressional testimony (Mar. 12, 2019); House Reports/hearings (Mar. 4-12, 2020).",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and SEC Rule 10b-5 (Count I, against Wells Fargo, Sloan, Parker, Duke, Shrewsberry)",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under PSLRA and Fed. R. Civ. P. 12(b)(6), the complaint must plead: (1) material misrepresentation/omission, (2) scienter, (3) connection to purchase/sale of security, (4) reliance, (5) economic loss, and (6) loss causation (Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005); Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011)). PSLRA requires particularity (15 U.S.C. §78u-4(b)) and strong inference of scienter (Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007)). Here, all elements are adequately pled. Material misrepresentations/omissions: Complaint specifies ~20 statements (¶¶144-208) with dates, speakers, exact quotes, and why false (e.g., Sloan's Dec. 4, 2018 'executing the plan' despite FRB rejections; cross-referenced to rejection letters ¶¶69-94). Omissions of regulator rejections, rebukes, extensions material as compliance was 'core operation' inflating stock by concealing asset cap prolongation risks (Matrixx). Scienter: Strong inference via (a) core operations doctrine (high-level execs on notices/rejections addressed to Sloan/Duke); (b) specific evidence (rejection letters to Sloan/Duke, internal emails 'biffed it,' Sloan apology to FRB, Duke admissions, Sloan/Duke proxy tampering ¶¶90-91); (c) GAAP violations unnecessary; (d) resignations/clawback/Sarf admissions (Tellabs). Reliance/loss causation: Fraud-on-market presumption (Basic Inc. v. Levinson, 485 U.S. 224 (1988)); corrective disclosures/stock drops detailed (e.g., Jan. 15, 2019 -2.4%/$3.4B on cap extension ¶¶219-22; total $54B, outpacing peers). Connection/economic loss obvious. No Twombly plausibility failure; allegations exceed PSLRA threshold."
        },
        {
          "claim": "Section 20(a) of the Exchange Act (Count II, against Insider Defendants: Sloan, Shrewsberry, Scharf, Parker, Duke)",
          "ruling": "sustained",
          "reasoning": "§20(a) requires primary §10(b) violation (sustained supra) and 'control person' status (culpable participation not required pre-Janus (Parmalat Capital Fin. Ltd. v. City of Madison Pension Dep't, 11 F.4th 106 (2d Cir. 2021), but 2d Cir. applies)). Insider Defendants plausibly alleged as controlling: senior positions (CEO/CFO/GC/Chair), signed Consent Orders, received rejection letters, approved statements/plans, direct involvement (e.g., Sloan/Duke extensions ¶¶77-106, proxy edits; Duke Risk Chair/point for regulators ¶26). Culpable participation via dissemination/control of false statements (e.g., Shrewsberry/Parker post-Sloan lies ¶¶189-208). Scharf pled despite late arrival (Oct. 2019): alleged statements (conference calls) and control as CEO. No dismissal warranted; discovery needed (In re Parmalat, supra)."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 50277,
      "completion_tokens": 1556,
      "total_tokens": 52703
    },
    "case_id": "nysd_20_cv_04494"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Lead Plaintiff Steven Christiansen brings this securities class action on behalf of himself and a class of purchasers of Spectrum Pharmaceuticals, Inc. ('Spectrum' or the 'Company') common stock during the Class Period from March 17, 2022, through September 22, 2022, inclusive. Defendants are Spectrum, a biopharmaceutical company developing oncology drugs including poziotinib ('pozi'), a tyrosine kinase inhibitor for previously treated non-small cell lung cancer ('NSCLC') with HER2 exon 20 insertion mutations; Thomas J. Riga, President and CEO; Francois J. Lebel, former EVP and Chief Medical Officer ('CMO'); and Nora E. Brennan, EVP and CFO. The alleged fraudulent conduct involves Defendants' material misrepresentations and omissions regarding the development of pozi, for which Spectrum sought accelerated approval ('AA') via a New Drug Application ('NDA') filed November 24, 2021, with a PDUFA date of November 24, 2022. Key misrepresentations include: (1) claims that Spectrum had 'optimized' the pozi dosage (e.g., Riga's March 17, 2022 statement 'we have learned to optimize' the BID dosage), when the FDA had repeatedly informed Defendants pre- and during the Class Period that dosing data was inadequate, efficacy low, toxicity high, and dose not optimized—a 'fatal flaw'; (2) assertions of FDA 'alignment' on the confirmatory PINNACLE Phase 3 trial design using 8 mg BID (vs. 16 mg QD in the NDA), when FDA explicitly stated no agreement and warned Defendants they proceeded 'at their own risk'; and (3) false statements that the PINNACLE Study was 'in progress,' 'initiated,' 'patients are being randomized,' and sites were opening/enrolling (e.g., May 12 and August 11, 2022 press releases and calls), when zero patients had enrolled as of September 2022, despite FDA emphasis on substantial enrollment by PDUFA. These hid FDA concerns from meetings (e.g., February 2022, May 18, July 28, September 8, 2022) and Spectrum's cash crunch motivating ATM stock sales (~24.5 million shares for ~$26.6 million). Truth emerged via FDA Briefing Document (September 20, 2022, ~37% stock drop), ODAC meeting (September 22, 2022, 9-4 vote against approval, ~31% drop post-halt), and CRL (November 25, 2022). Claims: Count I - §10(b)/Rule 10b-5 against all Defendants; Count II - §20(a) against Individual Defendants. Significant dates: NDA acceptance February 2022; Class Period start March 17, 2022 (Q4 2021 earnings call); PINNACLE disclosures May/August 2022; ODAC September 22, 2022 (Class Period end); Lebel resignation December 31, 2022.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive a motion to dismiss a §10(b)/Rule 10b-5 claim under the PSLRA and Iqbal/Twombly, the complaint must plead with particularity: (1) a material misrepresentation or omission, (2) scienter, (3) connection to purchase/sale of security, (4) reliance, (5) economic loss, and (6) loss causation. Here, all elements are plausibly alleged. Material misrepresentations/omissions are specifically identified (e.g., ¶¶ cited in Section VI: Riga's March 17 'optimize' statement, May 12/August 11 claims of 'patients being randomized' and FDA 'alignment' despite zero enrollment and FDA warnings of 'no formal agreement' and 'at own risk' per ODAC transcript/FDA Briefing Document). These are not puffery but verifiable historical facts contradicted by public FDA disclosures (e.g., ODAC statements by Drs. Drezner, Zirkelbach, Singh, Pazdur calling dose optimization a 'fatal flaw,' no PINNACLE enrollment). Duty to disclose arose from half-truths (e.g., touting study 'initiated' while omitting zero enrollment/delays). Scienter is strongly pled via core operations inference (pozi was Spectrum's lead drug/pipeline centerpiece), specific motive (cash burn, ~$26M ATM sales during period, Lebel/Brennan insider sales), and severe consequences (Lebel resignation post-ODAC, 75% R&D cuts). Confidential witness-equivalent via detailed FDA meeting allegations (pre-Class Period through September 8) shows Defendants' knowledge. Reliance presumed via fraud-on-the-market (efficient NASDAQ market, analyst coverage). Economic loss/loss causation clear: ~37% drop on FDA Briefing (first revealing FDA concerns/no enrollment), ~31% on ODAC (confirming), no recovery, tied directly to prior artificial inflation. No bespeaks caution doctrine applies as warnings were boilerplate/generic ('trials may be delayed') while risks had materialized. Claim survives against all Defendants; Brennan's involvement via Q2 10-Q signing/calls suffices at pleading stage."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "§20(a) control person liability requires: (1) a primary §10(b) violation, and (2) controlling person status (power to control primary violator + culpable participation). Primary violation sustained supra. Individual Defendants plausibly 'controlled' Spectrum: Riga (CEO, signed 10-Qs, led calls), Lebel (CMO, key FDA interlocutor, calls/press), Brennan (CFO, signed Q2 10-Q, calls, ATM approvals). 'Culpable participation' inferred from direct false statements/omissions in calls/press they made/signed, with scienter as above. No need for 'special proof' at motion stage; allegations of specific involvement suffice (e.g., Lebel's evasive August 11 enrollment answers despite knowledge; Riga/Brennan ATM orchestration amid misreps). Claim survives against all Individual Defendants."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 23526,
      "completion_tokens": 1313,
      "total_tokens": 25787
    },
    "case_id": "nysd_22_cv_10292"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "The complaint is a securities class action brought by Lead Plaintiff Genesee County Employees’ Retirement System, a Michigan public pension fund, on behalf of all persons who purchased or acquired DocGo Inc. ('DocGo') common stock during the Class Period (inferred from context as approximately September 2022 to September 15, 2023, encompassing key misstatements and culminating in corrective disclosures). Defendants are DocGo, a Delaware corporation headquartered in New York providing medical transportation and mobile health services via NASDAQ-traded stock (ticker: DCGO); Stan Vashovsky, co-founder, former CEO, and Chairman; Anthony Capone, former President and CEO (resigned September 15, 2023); and Andre Oberholzer, former CFO and later Treasurer/EVP. The alleged fraudulent conduct involves a scheme to mislead investors about DocGo's technological edge and growth prospects. Key misrepresentations include: (1) Capone's fabricated educational credentials—he falsely claimed a graduate degree in computational learning theory (a subset of AI) from Clarkson University and other degrees, repeatedly touting them in investor conferences (e.g., H.C. Wainwright Sept. 13, 2022; JPMorgan Jan. 12, 2023; Canaccord Aug. 9, 2023), proxies (April 29, 2022; April 26, 2023), SEC filings (e.g., Nov. 7, 2022 8-K), proposals, podcasts, and company bios to bolster DocGo's purported proprietary AI platform as its 'secret sauce' and differentiator in medical transport/mobile health; (2) Capone's inflation of a prospective U.S. Customs and Border Protection ('CBP') contract value to over $4 billion (nearly $1B/year) on August 9, 2023, claiming the $432M NYC HPD migrant contract provided credibility to win it, when it was actually worth ~$2B max and DocGo lost the bid; (3) False claims on August 9, 2023, that DocGo signed up over 3,000 migrants to New York State Medicaid via UnitedHealthcare ('UH') for long-term payer revenue, when DocGo had no UH contract in NY, did not enroll anyone in Medicaid, and could not become their primary care provider. These occurred amid scrutiny of DocGo's poor HPD contract execution (e.g., migrant complaints, threats, investigations). Individual Defendants oversaw/approved statements; Capone directly made many and had access to contrary facts. Corrective disclosures began September 10, 2023 (Times Union: CBP <$2B, no Medicaid enrollments, no UH contract), causing ~11% stock drop ($7.06 to $6.30); September 14, 2023 (Capone admits no grad degree), followed by September 15, 2023 8-K resignation and article, causing ~25% drop ($6.53 high to $4.88 low); total decline >56% from Class Period high $11.41 (Oct. 11, 2022). Claims: Count I (§10(b)/Rule 10b-5 against all); Count II (§20(a) control liability against all). Fraud on the market presumed reliance in efficient NASDAQ market.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the 1934 Act and SEC Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive a motion to dismiss a §10(b)/Rule 10b-5 claim under the PSLRA, the complaint must plead: (1) a material misrepresentation or omission, (2) scienter, (3) connection to purchase/sale of security, (4) reliance, (5) economic loss, and (6) loss causation, with particularity as to each statement's falsity and scienter via strong inference (Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007); Dura Pharms. v. Broudo, 544 U.S. 336 (2005)). Here, the complaint identifies specific statements (e.g., ¶¶70-85 listing Capone's conference remarks, proxy bios claiming 'M.S. in Computer Science from Clarkson University,' Aug. 9, 2023 Canaccord claims of $4B CBP contract and 3,000 Medicaid signups), why false/misleading (Capone's admissions, Times Union reports citing CBP/UH spokespeople, Clarkson no-record confirmation; ¶¶67-68, 87), and materiality (tied to core AI/tech platform as 'largest differentiator' per analysts/Defendants; massive CBP deal dwarfed 2022 revenue $440.5M; payer growth stability). Scienter strongly inferred: Capone's core role/knowledge of own fabrications (personal lies repeated 10+ times), 'core operations' doctrine for executives on pipeline/contracts (Matrixx Initiatives v. Siracusano, 563 U.S. 27 (2011)); Vashovsky/Oberholzer signed false proxies/8-Ks, oversaw hiring/promotions without verification despite repeated touting (reckless disregard); group pleading inappropriate but direct involvement alleged. Reliance presumed via fraud-on-the-market (Basic Inc. v. Levinson, 485 U.S. 224 (1988)) in efficient NASDAQ market with analyst coverage, SEC filings, price reaction. Economic loss/loss causation pled: specific partial disclosures (Sept. 10/14/15, 2023) revealed prior falsity, causing identifiable drops (10.76% then 25%, total >56%) negating confounding factors (BTIG analyst attribution). Plausibility under Iqbal/Twombly met; claims proceed to discovery."
        },
        {
          "claim": "Section 20(a) of the 1934 Act",
          "ruling": "sustained",
          "reasoning": "§20(a) control person liability requires: (1) primary §10(b) violation by controlled entity/person, and (2) 'control'—power to influence/direct primary violator's acts plus culpable participation (or recklessness) (17 C.F.R. §240.12b-2; In re Parmalat Sec. Litig., 376 F. Supp. 2d 472 (S.D.N.Y. 2005)). Primary §10(b) claim survives (see above), satisfying first element against DocGo. For Individual Defendants: high-level positions (CEO/Chairman, President/CEO, CFO) with 'power to influence' via board/management oversight, signing/disseminating false proxies/8-Ks/releases (e.g., Vashovsky signed 2022/2023 proxies; Oberholzer signed Nov. 2022 8-K), access to nonpublic info, direct involvement (oversaw Capone hiring/promotions, touted AI/Capone repeatedly). Culpable participation: prepared/approved false statements despite recklessness (no credential verification amid emphasis); Capone direct actor. Strong §10(b) scienter carries over. Complaint pleads PSLRA particularity; no dismissal warranted (e.g., not mere status, but specific acts). Motion denied."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 16034,
      "completion_tokens": 1517,
      "total_tokens": 18758
    },
    "case_id": "nysd_23_cv_9476"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs are the Retirement Plan for Chicago Transit Authority Employees (Lead Plaintiff for Exchange Act claims) and Oklahoma Firefighters Pension and Retirement System (for Securities Act claims), asserting a securities class action against Mobileye Global Inc. and Executive Defendants Amnon Shashua (CEO), Moran Shemesh Rojansky (CFO), Anat Heller (former CFO), and Daniel Galves (Chief Communications Officer). The complaint alleges a channel stuffing scheme during the Class Period (January 26, 2023 to August 1, 2024), where Defendants forced Tier 1 customers (e.g., ZF Group, Valeo, Aptiv, Magna, comprising ~70% of revenue) into annual minimum quantity commitments for EyeQ chips (90% of revenue), shipping 6-8 million excess units beyond demand (4-5M in 2021-2022, 2-3M in 2023), despite customer objections and declining OEM demand, as corroborated by confidential witnesses (FE 1 from Aptiv, FE 2 from Mobileye), industry standards (EDI forecasts, AIAG protocols), and year-end shipment spikes. Defendants touted demand-driven growth, conservative guidance, market-conditioned shipments, customer capacity, and 70% ADAS market share in earnings calls, SEC filings (e.g., 2022 10-K, Q1-Q3 10-Qs), press releases, and conferences, while concealing the scheme that inflated revenue to meet guidance/analyst estimates (e.g., without excess, missed 2022 guidance by $82-98M, 2023 by $120M+). Truth emerged: Jan 4, 2024 (6-7M excess inventory revealed, Q1'24 revenue -50%, 2024 rev stall; stock -24.5% to $29.97); Jan 25, 2024 (admitted full-year commitments made adjustment 'impossible'); Aug 1, 2024 (further guidance cut 13%, EyeQ volumes -25%, residual inventory; stock -22.5% to $16.28; total ~70% drop). Exchange Act claims: §10(b)/10b-5(b) (misstatements), §10(b)/10b-5(a),(c) (scheme), §20(a) (control). Securities Act claims (June 2023 $1.6B Secondary Offering): §11 (Offering Docs misstatements, Item 303/105 omissions), §15 (control). Losses tied to corrective disclosures.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5(b)",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under PSLRA, complaint must plead (1) material misrepresentation/omission, (2) scienter, (3) connection with purchase/sale, (4) reliance, (5) economic loss, (6) loss causation (Dura Pharms.). Here, well-pleaded facts identify dozens of specific statements (e.g., ¶¶138-190: shipments 'depend upon market conditions,' customer 'capacity,' growth from 'volume/ASP/demand'; 10-K/Qs denying routine min commitments) as false/misleading, as Defendants forced min commitments on top customers (70% revenue), shipped 6-8M excess EyeQ units despite forecasts/complaints (CWs FE1/FE2 attribute knowledge to Shashua/Heller), inflating revenue/guidance/market share. Materiality: analysts/investors lauded growth, stunned by disclosures (no prior notice), revised estimates 25-32%. Scienter strong inference: core EyeQ ops (90% rev), CWs (FE2: decisions 'went up to Amnon'; quarterly exec mtgs w/Heller), concentration (few customers), precise guidance beats suspiciously propped by excess (~5-8% volumes), GAAP risks (improper recognition?), no non-inferences equally compelling. Reliance/efficiency presumed (fraud-on-market). Loss causation: stock drops 24.5%/22.5% on partial truths (excess inventory, failed assurances), tracing to misstatements (analyst shock re visibility/demand). Plausibly states claim against Mobileye/Executives; survives Iqbal/Twombly."
        },
        {
          "claim": "Section 10(b) of the Exchange Act and SEC Rules 10b-5(a) and (c)",
          "ruling": "sustained",
          "reasoning": "Scheme liability requires deceptive device/act/practice independent of misstatements, with scienter/reliance/loss causation (Lorenzo v. SEC; SEC v. Zandford). Complaint plausibly alleges scheme: (i) imposed atypical full-year min commitments (made adjustment 'impossible,' per admissions/CW1), (ii) shipped excess (6-8M units) over objections/forecasts, (iii) concealed via mismatched statements, (iv) cannibalized future rev (2024 stall). Deceptive acts beyond statements (e.g., forced shipments despite EDI data), half-truths (partial commitment disclosures w/o risks/scale), primary to fraud (propped numbers). Scienter as above (core, CWs, motive). Same reliance/loss causation. Plausibly distinct from 10b-5(b), survives against all Defendants."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "Requires primary §10(b) violation + culpable control (power to direct + culpable participation/direct/tortious act; §20A scienter not required post-Lorenzo). Primary survives (above). Executives (Shashua/Rojansky/Heller/Galves) high-level (CEO/CFOs/CCO), signed filings, spoke on calls/conferences re demand/inventory/growth, prepared/disseminated misstatements (CW2: reported to Shashua chain), directed scheme (FE2). Culpable: knowing/reckless participation. Plausibly states control person liability."
        },
        {
          "claim": "Section 11 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Strict liability/neglience for registration statement/prospectus material misstatements/omissions (15 U.S.C. §77k; no scienter/CA needed; Omnicare for opinions). Offering Docs (S-1/Prospectus inc. 2022 10-K/Q1 10-Q) contained same misstatements (¶¶285-293: 'generally no' min qty contracts, shipments 'depend[ ] upon market conditions,' growth from demand; partial disclosures minimized), omitted Item 303 trend (known excess 4-5M pre-Offering, ongoing 2023 buildup 'reasonably likely' to materially impact future rev via drawdowns; materiality obvious, post-China Bridge). Item 105 risk omission (speculative from decoupling sales/demand). Reasonable investigation due diligence lacking (signers Shashua/Heller had access to customer data/CWs). Oklahoma Firefighters trace purchases (30k shares @ $42 Offering price). Negative CA defense premature (motion to dismiss). Survives against Mobileye (issuer), Shashua/Heller (signers)."
        },
        {
          "claim": "Section 15 of the Securities Act",
          "ruling": "sustained",
          "reasoning": "Control liability under §15 requires §11 primary + 'controlling person' (power to direct + culpable participation; strict if issuer liable). §11 survives. Shashua (CEO/Dir), Heller (CFO signer) senior execs controlled contents/dissemination (signed S-1, managed ops), culpable via failure to investigate known trends (access to data). Plausibly states claim."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 43224,
      "completion_tokens": 1642,
      "total_tokens": 45986
    },
    "case_id": "nysd_24_cv_310"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test2",
    "success": true,
    "response": {
      "summary": "Plaintiffs Dominik Dumancic, Luis Vicente Davidoff Cracasso, and Richard Wilkinson bring this securities class action on behalf of all persons who purchased American Airlines Group Inc. ('American' or the 'Company') securities between July 20, 2023, and May 28, 2024 (the 'Class Period'). Defendants are American, a major U.S. airline, and its executives: Robert D. Isom, Jr. (CEO), Devon E. May (CFO), and Vasu S. Raja (former Chief Commercial Officer, departed June 2024). The complaint alleges Defendants fraudulently misrepresented the success of American's 'Modern Retailing' strategy, implemented starting December 2022, which shifted sales from traditional EDIFACT/global distribution system (GDS) channels (used by travel agencies, TMCs, and corporates) to direct/NDC channels to cut costs and boost control/revenue. Key factual allegations include: (1) April 2023 removal of 40% of fare content (e.g., basic economy) from EDIFACT, tying incentives to NDC adoption via restrictive July 2023 contracts, reducing perks (e.g., Flex Funds, concierge status), and canceling SMB agency contracts; (2) CW1 (Travel Agency Account Manager, 2019-Jan. 2024) and CW2 (Retail Business Manager, >30 years until Jan. 2024) testimony that agencies/TMCs/corporates resisted due to tech hurdles (e.g., no duty-of-care data, servicing issues), leading to swift share loss (PSP <90%, 15%+ booking drops, drop to tertiary provider status), confirmed by internal tools (SalesLink Insights, PRISM, IATA reports); (3) Defendants' access to these metrics and evasive responses to analyst questions; (4) Throughout Class Period, Defendants touted 'encouraging' NDC adoption, 'durable' corporate demand, stable share, and issued/reaffirmed inflated 2Q/FY2024 guidance ($2.25-$3.25 EPS, $2B FCF) in SEC filings (10-Qs, 10-K), earnings calls, conferences, despite knowing contrary facts. Corrective disclosures: May 28, 2024 (Raja departure, slashed 2Q guidance); May 29 Bernstein Conference (Isom admits strategy drove customers away, poor execution, Q1 deviation from peers known but hoped to reverse); July 25, 2024 (2Q results: $750M H1 revenue hit from strategy, FY EPS cut to $0.70-$1.30). Stock fell 13.5% on May 29 (to $11.62), largest drop since 2020; peers stable. Analysts attributed to Company-specific strategy failure. Claims: (1) §10(b)/Rule 10b-5 against all Defendants (material misstatements/omissions, scienter, reliance via efficient market, loss causation); (2) §20(a) against Individual Defendants (control person liability).",
      "claim_rulings": [
        {
          "claim": "Section 10(b) of the Exchange Act and Rule 10b-5",
          "ruling": "sustained",
          "reasoning": "To survive dismissal under PSLRA/Fed. R. Civ. P. 12(b)(6), complaint must plead: (1) material misrepresentation/omission, (2) scienter, (3) reliance, (4) economic loss, (5) loss causation, with particularity (15 U.S.C. §78u-4(b)). Here, Plaintiffs identify ~20 specific statements (e.g., July 20, 2023 2Q Earnings Call: Raja on 'durability' of demand; Isom/others on 'encouraging' trends, guidance reaffirmations in 1Q 2024 filings/call despite Q1 peer deviation), explaining falsity via contemporaneous CW1/CW2 accounts (share drops post-July 2023 contracts, NDC non-adoption), internal data access (SalesLink/PRISM/IATA), and risk factor omissions framing harms as hypothetical. Materiality plausible: statements core to guidance/investor confidence in strategy critical to ~29% revenue (agency/corporate). Scienter strong inference via: (i) core ops doctrine (distribution central to passenger revenue, 92% of total); (ii) specific access (Raja/IATA; all via reports/meetings); (iii) evasive call responses; (iv) Bain review (commissioned pre-May 2024); (v) post-class admissions (Isom: Q1 known issues, $750M H1 hit, 'moved too fast'); (vi) Raja ouster tied to strategy; outweighs contrary (no SARs/confessions). Reliance presumed (fraud-on-market: efficient Nasdaq market, high volume/analyst coverage). Economic loss/loss causation: May 29 drop (13.5%, $1.82) on partial disclosures specifically tying shortfalls to strategy (vs. peers flat); analyst reactions confirm (Bernstein/Barclays: Company-specific, positive for DAL/UAL). Plausible 'corrective disclosure' chain; survives as to all Defendants (group pleading ok for company/insiders; Raja/Isom/May direct attributions)."
        },
        {
          "claim": "Section 20(a) of the Exchange Act",
          "ruling": "sustained",
          "reasoning": "§20(a) requires: (1) primary §10(b) violation; (2) control (power to influence/direct primary violator); (3) culpable participation (not in good faith). Primary claim sustained above. Individual Defendants (senior execs: CEO/CFO/CCO) plausibly controlled Company content (signed filings, spoke on calls/conferences, directed strategy). Culpable participation via direct misstatements (e.g., Isom: 'nothing...suggest[ing] we’re not on the right path' Mar. 2024 despite data; Raja: 'revenues coming back very materially' Apr. 2024; May: guidance) and omissions with scienter (access/inaction). No good faith: knew falsity via metrics/admissions. Survives against all Individuals."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 54894,
      "completion_tokens": 1314,
      "total_tokens": 56898
    },
    "case_id": "txnd-4_24-cv-00673"
  }
]